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ABSTRACT OF THE DISSERTATION
Splice Factor SFRS6: Regulation by p53 and Effect on IL-24 Splicing
by
Erin L. Schmidt
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Toma Linda University, September 2010
Dr. Penelope Duerksen-Hughes, Chairperson

Alternative splicing of RNA transcripts is emerging as a major mechanism for
expanding the proteome. Splice pattern changes are found in numerous diseases and
cancers, indicating the importance of tight control over this process. While the
mechanism of splicing has been described in detail, it is less clear how a cell is able to
modify its splicing patterns in response to different conditions. Our lab previously
demonstrated that DNA damage can induce SFRS6, the gene coding for splicing factor
SRp55, thereby leading to changes in the splicing patterns of several target genes related
to survival and apoptosis. We also showed that this induction can be inhibited by p53. In
this study we investigated the mechanism by which p53 inhibits SFRS6 transcription.
Utilizing a luciferase reporter plasmid, we found that two putative p53 REs in the SFRS6
promoter were critical for this inhibition. ChIP and EMSA were then employed to
confirm that p53 activated by DNA damage binds directly to these REs on the SFRS6
promoter. Because SFRS6 is modulated by p53 in response to DNA damage, we
investigated the downstream effects of this splice factor. SFRS6 regulates the splicing of
many genes related to DNA damage and apoptosis, one of which is IL-24. Silencing of
SFRS6 results in an increase in a splice variant that lacks exons 2 and 3, while over
expression results in an overall shift away from the larger splice isoforms. In examining

xviii

the splicing of IL-24, we identified numerous splice variants that have not been
previously reported. We characterized these isoforms and have now described five novel
splice variants of this important tumor suppressor. We examined the function of these
novel variants and found that several of them induce apoptosis in tumor cells with
different efficacies, while one of them does not. The results of this study provide further
insight into functional splicing regulation as it is controlled by upstream events.
Understanding the control of splicing has the potential to provide novel clinical insights
into the ways that disordered splicing plays a role in disease. In particular, the novel
isoforms of the tumor suppressor IL-24 suggest additional options for the treatment of
various cancers.
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CHAPTER ONE
INTRODUCTION

Cancer
Overview and Incidence
The group of diseases collectively referred to as “cancer” vary widely in
characteristics, demographics, and severity. Indeed, there are more than 100 types of
cancer. All of these types of cancer, however, refer to a condition of normal cells
becoming abnormal, dividing without control and spreading to other tissues and organs.
This involves the malfunction of genes controlling cell growth and division. While 5% of
cancers are strongly hereditary, the rest result from acquired damage or mutation to these
genes. This damage can be environmental (cigarette smoke, UV exposure), caused by an
infectious agent (HBV, HPV, HIV), or result from random mutation. Cancer is a world
wide health concern. It was the cause of 7.6 million deaths around the world in 2007, and
is the second leading cause of death in America. In the United States, approximately 1.5
million people will be diagnosed with cancer in 2009, and 565,000 will die from the
disease (Jemal, 2009). The overall cost of cancer, including direct medical costs, indirect
morbidity, and lost productivity was estimated to be $219 billion in 2007 (American
Cancer Society 2008).
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Cancer can be viewed in two ways, either by analyzing the complexity of and
differences between the various forms of the disease, or by taking a reductionist approach
to look at the broad similarities shared by all cancers. From a research standpoint, both
approaches are important, and both can yield medically relevant treatments.

Cancer Treatment
Many of the treatments used for cancer target the broad similarities shared
between all types of the disease. The physician aims to eliminate these rapidly
proliferating, abnormal cells from the patient. These treatments are often used in
combination. Surgery may be performed to remove the tumor mass. Targeted ionizing
radiation may be used to kill the cancer cells. Radiation kills normal cells as well, but
they are better able to recover from the damage; additionally, the beam can be targeted
specifically to the area of the tumor, minimizing damage to healthy tissue. Chemotherapy
is also used as a cancer treatment. The types of chemotherapy drugs used to treat many
different cancers target rapidly dividing cells; this strategy reduces but does not eliminate
the effect of the drugs on normal cells.
The therapies described above target different types of cancer regardless of the
molecular characteristics of each case. However, our growing understanding of the
complexities of cancer, including genetic mutations and disrupted cellular pathways,
enables physicians to consider personalized medicine, using molecular therapies and
targeting the treatment for each patient’s cancer to the specific aberrations causing it. For
example, estrogen receptor positive breast cancers receive growth signals when estrogen
binds to the receptor (Cleator et ak, 2009). Selective estrogen receptor modifiers
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Figure 1. Schematic illustration by Hanahan and Weinberg (Hanahan and Weinberg, 2000) of some of the signaling
pathways within the cell related to growth, differentiation and apoptosis. This illustrates the complexity of the network
of pathways that can become deregulated in cancer.
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(SERMs) such as tamoxifen block this receptor signaling. This can be a very effective
treatment, provided that the estrogen receptor status of the patient’s tumor is known
(Swaby et ah, 2007). Another example of a targeted treatment is imatinib (Gleevec),
which is used for patients with chronic myelogenous leukemia (CML). Patients with
CML have a chromosomal translocation (the “Philadelphia chromosome”) that results in
the oncogenic bcr-abl fusion gene, a tyrosine kinase (Heisterkamp et ah, 1985). Imatinib
specifically inhibits this constitutively active tyrosine kinase and is a remarkably
effective treatment for patients with this specific type of cancer (Cilloni and Saglio,
2009).
The ever growing body of cancer research continues to uncover new molecular
targets for therapy as more oncogenic pathways are elucidated (Figure 1). As these
complexities come into focus from the growing body of cancer research, however,
broader categories for understanding cancer begin to crystallize. Therapies are being
developed that target these broader characteristics of cancer in addition to those therapies
that target one specific tumor type. Examples of this type of treatment include
angiogenesis inhibitors (Folkman, 2006), which block the ability of the tumor to increase
its blood supply, or various methods for triggering apoptosis (Mahmood and Shukla,
2010, Constantinou et ah, 2009). To clarify how these and other broad classes of drugs
are being developed, an understanding of these cancer archetypes is necessary.
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Figure 2. Schematic illustration by Hanahan and Weinberg (Hanahan and Weinberg,
2000) of the 6 hallmarks of cancer. This figure represents the broad categories into
which we can fit the complex pathways illustrated in figure 1.
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Molecular Development of Cancer
The Hallmarks of Cancer
The complex body of cancer research contains an ever-increasing articulation of
specific molecular changes that can contribute to the development of cancer. However, in
2000, Hanahan and Weinberg proposed a consolidation of this complexity into six
alterations in cellular physiology that are characteristic of all cancers (Hanahan and
Weinberg, 2000) (Figure 2). Each of these alterations could be arrived at by any number
of molecular mechanisms, and they can occur in any order.
The first two hallmarks are related to growth signals. In normal tissue, the
quiescence or proliferation of cells is tightly regulated. Anti-proliferative signals keep
most cells quiescent, and growth signals are required before the cells can become
proliferative. Cancer must overcome these two controls, and so the first two hallmarks of
cancer are self-sufficiency in growth signals and insensitivity to anti-growth signals.
Cells may acquire the ability to make their own growth factors (such as PDGF), or over
express the receptors for those growth factors, creating a positive proliferative feedback
loop and eliminating their dependence on other cells for these signals (Alimandi et al.,
1995). Anti-growth signals may be overcome by developing mutations in one of the
pathways that blocks cell cycle progression, such as the retinoblastoma (pRb) pathway.
Many feedback signals progress through this pathway, and mutations to any number of
molecules may lift this constitutive proliferative inhibition (Fynan and Reiss, 1993).
The next two acquired capabilities are related to survival. Cancer cells must be
able to evade apoptosis, which is a critical mechanism for eliminating damaged or
malfunctioning cells, and is now recognized as a major defense against cancer. In order to
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proliferate out of control, cells must avoid elimination by this protective function.
Cancers can develop apoptotic resistance in many ways, the most prominent being
inactivation of p53, the “guardian of the genome” (Efeyan and Serrano, 2007). Cancer
therapies may attempt to trigger apoptosis by targeting another undamaged apoptotic
pathway, for example, by utilizing death receptors such as TRAIL, by triggering the
mitochondrial pathway through the BCL-2 family of proteins, or by targeting the lAPs
(Inhibitor of Apoptosis Proteins) (Fulda and Debatin, 2004). Additionally, cells must be
able to overcome their intrinsically limited lifespan, or the cancer would grow for a
period and then die on its own. And so the fourth hallmark of cancer is limitless
replicative potential, which is observed when cells overcome the limitations set by
telomeres (Artandi and DePinho, 2010) and senescence (Serrano et al., 1997).
The last two acquired hallmarks of cancer enable the cancer cells to sustain
themselves and spread. As cancer grows, it requires nutrient supply; all cells in a tissue
must be within approximately 100 pm of a blood vessel. The ability to promote
angiogenesis requires the cells to activate angiogenic signals and block anti-angiogenic
signals (Pang and Poon, 2006). And finally, cancer would not be so difficult to treat if it
remained in the tissue compartment where it developed. But nearly all cancers eventually
invade the surrounding tissue and begin to metastasize to different locations throughout
the body. Metastases cause 90% of cancer deaths (Mehlen and Puisieux, 2006).
Although considered to be a singular hallmark of cancer, metastatic progression proceeds
through the acquisition of a number of traits required for cells to disseminate to other
tissues. The cells must have acquired several of the other hallmarks in order to
metastasize, including self-renewal and angiogenesis. Additionally, they must have
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developed motility and the ability to survive when detached from their native tissue, be
able to attach to new tissues, and to recruit local growth, survival and angiogenic signals
in the new tissue (Gupta and Massague, 2006).

Acquiring the Hallmarks
While almost all cancers eventually acquire all six of these hallmarks, the
mechanism by which they accumulate varies both chronologically and mechanistically. It
is thought that the capabilities can accrue in almost any order. Furthermore, the ways in
which a cell can acquire molecular changes that represent the “hallmarks” of cancer are
numerous. Each hallmark is characteristic of an entire pathway, or network of pathways
that keep cellular proliferation under control, and as such, any number of acquired
mutations can disrupt or change one of these pathways, or activate a new pathway
(Krizman et ah, 1999; Stratton et ah, 2009; Tomlinson, 2001). Two sets of genes that are
linked to cancer development are oncogenes and tumor suppressor genes (Spandidos,
2007). Oncogenes are normally not expressed, but under certain circumstances or when
various controls are eliminated by mutation or inactivation, oncogenes are expressed and
cause cells to survive and proliferate when they would normally be quiescent or succumb
to apoptosis. Tumor suppressor genes are normally active in the cell and function to
regulate proliferation. When these genes are damaged by a loss-of-function mutation, it
can lead to the cell acquiring one of the hallmarks described above.
Many of the molecular changes that occur in cancer are not clearly understood.
One such change is related to alternative mRNA splicing. Wide-ranging aberrant splicing
is observed in cancer cells, and this aberrant splicing has even been proposed as a cancer
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biomarker (Brinkman, 2004; Skotheim andNees, 2007; Venables, 2004). To understand
how such splicing changes might occur, it is necessary to have a clear understanding of
mRNA splicing.

Alternative mRNA Splicing
Overview of Alternative Splicing
Eukaryotic genes are made up of a complex series of exons interspersed with non
coding intron sequences that must be eliminated or “spliced” out before proteins can be
transcribed (Black, 2003). This process is accomplished by mRNA splicing, which is
emerging as a critical player in the regulation of gene expression and as a method for
expanding the proteome. The estimated number of human genes before the completion of
the human genome project was 100,000 (Guyer and Collins, 1993). After its completion,
researchers were surprised to learn that there were in fact closer to 30,000 genes
(Claverie, 2001), and the estimated number has recently been suggested to be closer to
20,000 (Clamp et ah, 2007). Various analyses estimate that more than half of human
genes are alternatively spliced (Johnson et al., 2003; Kan et ah, 2001). The average gene
generates two to three transcripts, some many more (Stamm et al., 2005), greatly
expanding the number of protein products that can be produced from a mere 20,000
genes.
Additionally, alternative mRNA splicing allows much more complex control over
gene expression than simple modification of promoter activity, which can only regulate
the level of mRNA expression. Alternative splicing, however, can produce mRNAs with
different stability, code for a protein in a different reading frame thus creating an entirely
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different amino acid sequence, or introduce a stop codon leading to a truncated protein
product. Alternatively spliced mRNAs can alter the function of the protein product by
splicing out regions coding for a particular domain, thus modifying the activity of the
protein, changing enzymatic activity and kinetics, or altering intracellular localization
(reviewed by (Stamm et ah, 2005)). Additionally, there are many cases now described
where protein isoforms produced by alternatively spliced transcripts modify the activity
of the primary isoform by heterodimerizing, by blocking receptor sites, or by other means
(Denessiouk et ah, 2008; Sahoo et al., 2008; Unoki et ah, 2006).

The Spliceosome
The complex job of splicing mRNA is performed by the spliceosome, an
elaborate group of proteins and ribonucleoprotein particles. Five small nuclear
ribonecleoprotein particles (snRNPs) form the core of the spliceosome (Figure 3, Upper
Panel). At the 5’ end of the intron, a poorly conserved consensus sequence beginning
with GU is recognized by Ul. U2 binds the branch point at the 3’ end, guided by U2AF
to recognize the polypyrimidine tract ending with AG. The tri-snRNP complex,
U4/U5/U6 joins, completing the core spliceosome, which rearranges and releases Ul and
U4 before catalyzing the splicing reaction (reviewed in (Black, 2003)). The core
spliceosome is assisted in splice site recognition by a large number of auxiliary proteins
(Figure 3, Lower Panel). Most of these auxiliary splice factors belong to one of two
families: the SR family of proteins, or the heterogeneous nuclear ribonuceloproteins
(hnRNPs) (Graveley, 2000; Krecic and Swanson, 1999). Splice factors recognize and
bind to weakly conserved elements on the pre-mRNA. These elements include ESEs
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Figure 3. Upper Panel: Schematic illustration of the core spliceosome components from
Luhrmann, http://www.mpibpc.mpg.de/groups/pr/PR/2Q08/08 10 eng RN/. The 5 core
Platzer,
snRNPs are illustrated. Lower Panel: Schematic illustration by
http://www.sfb604.uni-iena.de/Proiect BIO (Platzer).html, Several splice site enhancer
and silencer sites are shown, as well as some of the additional regulatory molecules—
hnRNPs and SR proteins—that assist the spliceosome in recognizing the intron-exon
boundaries.
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(exonic splicing enhancers), which are bound by specific SR proteins, and provide a
general mechanism for defining the exon. Once bound to the ESE, SR proteins can recruit
other spliceosomal elements. Additionally, elements that block splicing are known as
ESSs (exonic splicing silencers). ESSs are commonly bound by hnRNPs, and this blocks
the assembly of spliceosomal elements. The weak binding of the individual spliceosomal
elements allows for the recognition of splice sites to be regulated by the specific
combination of weakly bound proteins (Black, 2003; Stamm, 2002). This combinatorial
control allows for high fidelity and control of splice site recognition. Tight control over
this process is critical, as the process of splice site selection and mRNA splicing affects
more than half of human genes.
Regulation of SR protein activity is an important factor in the regulation of
alternative splicing, and splice factor expression profiles can vary dramatically between
tissue types. It is easy to see, therefore, how easily modifications to alternative splicing
could lead to many of the molecular changes necessary for a cell to acquire the
characteristics of cancer. And indeed, the aberrant splicing seen in cancer is accompanied
by a dramatic shift in expression of splicing-associated proteins compared to their
expression in normal tissues (Skotheim and Nees, 2007).

Alternative Splicing in Cancer
As mentioned above, many diseases, including cancer, are increasingly associated
with or caused by aberrations in alternative splicing. Wide ranging aberrant splicing is
observed in cancer cells, and this aberrant splicing has even been proposed to be a cancer
biomarker. An extensive analysis of mRNAs from the RefSeq database
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Figure 4. Microarray heatmap by Skotheim (Skotheim and Nees, 2007). Information
from a public microarray database was combined by the authors into a single heatmap
showing expression of splice factors in normal tissue compared to cancer tissues and cell
lines. The altered splice factor expression in cancer is clearly illustrated.
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(,httD://www.ncbi.nlm.nih.gov/RefSeq/) found that GT-AG splice junctions were used less
frequently in tumors; 845 alternative splice variants were significantly associated with
cancer (Wang et ah, 2003). While the specific molecular mechanism (or mechanisms)
for these consistent observations are not clear, microarray data demonstrates that the
expression of mRNAs coding for splicing-associated proteins is dramatically different in
cancers and cancer cell lines from that seen in normal tissues (Skotheim and Nees, 2007)
(Figure 4).

Model Pathway
While relatively little is known about transcriptional control of splice factors, it
was first hypothesized and then proven, in our laboratory and others, that p53 can act as a
regulator of SR protein expression levels. In particular, it down-regulates the expression
of SRp55 and SRp20 (Daoud et ah, 2003; Filippov et ah, 2008). Expression data from a
public microarray database corroborates these findings, demonstrating a tendency for
genes encoding SR proteins to be down-regulated in response to p53, and for hnRNPs to
be up-regulated in response to p53 (http://www.ba.itb.cnr.it/p53FamTag/) (Table 1).
These observations connecting p53 to splicing changes provide one possible mechanism
underlying the aberrant splicing seen in cancer.
This connection between p53, an important tumor suppressor gene, and
alternative splicing, which is commonly disordered in cancer, leads to the question of
what genes are affected by the altered expression of specific splice factors, alone or in
combination. The answer to this question is likely to be “many,” and so to begin to
address this issue, we chose to look at a single pathway. In this study, we focus on the SR
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family protein SRp55, coded for by the gene SFRS6. It has already been demonstrated
that this gene is down-regulated by p53 (Filippov et ah, 2008). To further investigate the
effects of this pathway, we focused on the effect of SRp55 on one of its splicing targets,
Interleukin-24 (IL-24) (Figure 5).

p53
One of the most prominent tumor suppressor genes is p53, commonly referred to
as the “guardian of the genome” (Efeyan and Serrano, 2007). It is mutated or lost in
approximately 50% of human cancers (Hollstein et ah, 1991). Its many functions include
involvement in cell cycle regulation, apoptosis, development and differentiation, DNA
repair, and cellular senescence (Hofseth et ah, 2004; Pietsch et ah, 2008). Most of its
functions are carried out through its function as a transcription factor (Laptenko and
Prives, 2006). p53 is normally maintained at low levels by Mdm2, but in response to
DNA damage or other stress, p53 levels increase, and tetramers of the protein bind to
response elements of genes, many of which are related to DNA repair, cell cycle
progression and apoptosis (Brooks and Gu, 2003). p53 can function as both a
transcriptional activator and repressor, although it is best known for activating target
genes. Although this function is better understood, microarray analysis reveals that the
proportion of genes activated and repressed by p53 are approximately equal (Kannan et
al., 2001). Transcriptional repression by p53 appears to be more complex than activation,
and multiple mechanisms have been reported. Several studies report direct binding of p53
to the promoters of genes inhibiting expression. (Hoffman et al., 2002; Johnson et al.,
2001; Yang et al., 2008). Others report more complex mechanisms; p53 may interact with

19

Gene !M

p53

p63

p73

p53 REs

SR proteins

1

SFRS1
SFRS3

*

*

*

SFRS4
SFRS6

1
2

4/

2

SFRS7

*

3

SFRS9

*

1

SFRS10

3

SFRS11

2

SFRS12

*

*

4—>

3

*

2

hnRNP
HNRPA1
HNRPH1

3

HNRPH2

1

HNRPF

4

RBMX

*

PTBP1

1

*

1

*

Survivin
Fas

*

T

3

*

't'

3

Table 1. Regulation of splicing factor expression by over-expression of p53 family
members. Expression data was retrieved from the public microarray database available at
http://www2.ba.itb.cnr.it/p53FamTaGA and the microarray experiment is described in
Sbisa et ah, 2007. A gene was considered to be down-regulated (down arrow) or upregulated (up arrow) if it showed significantly lower or higher expression levels at any
analyzed time point following the induction of p53, p63 or p73 isoforms. Expression
profiles of survivin and Fas are included as examples of genes that are well-known to be
repressed or activated by p53, respectively. The right column shows number of predicted
p53 Responsive Elements within the gene.
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Figure 5. Working Model. Our working model demonstrates the connection between an
external event (DNA damage) and a change in splicing response. We propose that when
DNA is damaged in p53 expressing cells, p53 binds to the Responsive Elements on the
SFRS6 promoter, reducing the expression of SRp55. In these cells, the normal p53
response to damage is carried out in the cell, leading to cell cycle arrest and possibly
apoptosis. However in p53 deficient cells (as is the case in approximately 50% of human
cancers), the transcription of SFRS6 proceeds uninhibited after DNA damage, leading to
increased expression of its protein product, SRp55, and a variety of splicing changes in
the cell. Among those genes affected by SRp55 is IL-24, an important tumor suppressor
gene.
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transcription factor Sp-1 and repress transcription via Sp-1 recognition sites on the
promoter (Innocente and Lee, 2005; Wilson et al., 2009). Promoter methylation initiated
by p53 binding to DNMT-1 can also lead to transcriptional repression (Esteve et al.,
2005). p53 can also target G2/M promoters for repression via interaction with NF-Y
(Imbriano et al., 2005).
As mentioned above, p53 has been shown to generally down-regulate the
expression of SR proteins and up-regulate the expression of hnRNPs. Additional reports
demonstrate that p53 status can influence the splicing patterns of several molecules,
including CD44 (Filippov et al., 2007), MDM2 (Chandler et al., 2006; Schlott et al.,
2004), POLE (Disher and Skandalis, 2007), and Fas (Filippov et al., 2008). These
observations relating p53 to cancer-related splicing changes are particularly important
because p53 is mutated in more than half of all human cancers.

SFRS6 and SRp55
The SFRS6 gene codes for SRp55, a member of the serine/arginine-rich (SR)
protein family. This family of proteins plays an important role in both constitutive and
regulated mRNA splicing. Members of this family act by binding to purine-rich exonic
splicing enhancers (ESEs) found near the intron/exon boundary. SR proteins are known
to influence alternative splice site selection in both a tissue-specific (Tran and Roesser,
2003; Tran et al., 2003) and concentration-dependent (Chiu and Ouyang, 2006) manner.
Understanding the regulation of SR proteins is therefore critical to unraveling the
complexities of alternative mRNA splicing and its role in cellular processes. One of the
known regulatory mechanisms for SR proteins involves phosphorylation of the
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serine/arginine dipeptide-rich region, known as the RS domain. This phosphorylation can
affect activity and localization of the protein. SRp55 in particular is regulated by DRB,
which specifically induces hyperphosphorylation in this protein, but not in other SR
proteins (Lai et ah, 2003). Additionally, protein kinase Clk/Sty targets SRp55 for
proteasomal degradation (Lai et ah, 2003). Finally, the SR-related protein Pnn directly
affects the expression of SRp55 (Chiu and Ouyang, 2006).
While many of the SR proteins act together, SRp55 is particularly ubiquitous, and
has been found to uniquely contribute to a number of different splice site decisions. It
binds to ESEs that regulate the inclusion of exons in cardiac troponin T (Nagel et ah,
1998) and FGFR1 (Jin and Cote, 2004). SRp55 is involved in the regulation of calcitonin
splicing, and different levels of the SR protein contribute to the tissue-specific variation
in calcitonin levels (Tran and Roesser, 2003; Tran et ah, 2003). Of particular interest in
the field of cancer biology, SRp55 appears to regulate angiogenesis in several different
ways. Tissue factor (TF), an initiator of coagulation, has two splice isoforms, a
transmembrane coagulant form and a soluble form that is highly proangiogenic. This
splicing decision is regulated via the PI3K/Akt pathway, which influences the
phosphorylation of SRp55 (Chandradas et ah, 2010; Eisenreich et ah, 2009; Tardos et ah,
2008). SRp55 is also able to influence angiogenesis by affecting the splicing of VEGF,
which has a strongly pro-angiogenic isoform and a strongly anti-angiogenic isoform,
differentiated by splicing of exon 8 (Nowak et ah, 2008; Nowak et ah, 2010; Qiu et ah,
2009).
Our lab has been studying the way in which SRp55 is involved in the cellular
response to DNA damage. We initially found that SFRS6 was up-regulated in response to
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DNA damage, but only in p53-deficient cells. Silencing SFRS6 in these cells led to an
increase in cell viability following DNA damage, indicating that SRp55 was contributing
to the p53-independent damage response (Filippov et ah, 2007). Further investigation
revealed that the splicing of several apoptosis-related genes was modified by SRp55,
including KSR1, ZAK, Fas, and IL-24 (Filippov et ah, 2008).

IL-24
Discovery and Characterization ofIL-24
Interleukin-24 (IL-24) is a cytokine that was classified as a part of the IL-10
family of cytokines based upon common chromosomal location (lq32), a conserved
signal sequence, and its binding to members of a shared receptor family, specifically IL20R1/IL-20R2 and IL22R1/IL-20R2 (Caudell et ah, 2002). IL-24 was originally
described as melanoma differentiation-associated gene 7 (mda-7) in studies identifying
transcripts that were differentially expressed in melanoma cells induced to terminally
differentiate (Jiang et al., 1995). IL-24 expression is up-regulated in melanoma cells
stimulated to terminally differentiate and undergo apoptosis. It is constitutively expressed
in normal melanocytes, and the expression level decreases progressively in benign nevi,
in situ melanoma, invasive and metastatic melanoma (Jiang et al., 1995). These findings
supported the putative role of IL-24 as a tumor-suppressor. One prediction arising from
such studies was that IL-24 might be able to negatively impact tumor growth and
survival. To test this prediction, a replication-incompetent adenoviral vector containing
the full-length IL-24 gene sequence was constructed for use in cell culture and animal
models (Su et al., 1998). Over-expression of IL-24 was found to suspend growth and
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induce apoptosis in many different tumor cell types, including those representing
melanoma (Lebedeva et ah, 2002), breast cancer (Su et ah, 1998), pancreatic cancer (Su
et ah, 2001), prostate cancer (Lebedeva et ah, 2003), lung cancer (Saeki et ah, 2000),
malignant gliomas (Su et ah, 2003; Yacoub et ah, 2003), hepatomas (Chen et ah, 2005),
renal carcinoma (Yacoub et ah, 2003), ovarian cancer (Leath et ah, 2004), and others,
while having no apparent effect on normal cells and cell lines. Additionally, injection of
the construct into solid tumors caused a reduction in the size of tumors, enhanced the
lethal effects of radiation on tumor cells, and displayed potent antitumor bystander
activity. Phase I/II clinical trials are currently underway in humans, but only one study
has been completed (Cunningham et ah, 2005; Tong et ah, 2005). These researchers
reported the results of an intratumoral injection of Ad-Mda-7, named INGN-241, in
patients with a diverse assortment of refractory cancers. The findings from this study
indicate safety even at the highest dose, and some reduction in the tumor size at the site
of the injection.
While research has proceeded rapidly in the area of tumor suppression, there
remains controversy regarding the mechanism of action of IL-24, with some groups
contesting its ability to selectively induce apoptosis in cancer cells as recently as 2008
(Kreis et ah, 2007; Kreis et ah, 2008).

The Tumor Suppressor Functions ofIL-24
IL-24 functions intracellularly to induce apoptosis and inhibit tumor
growth
Many of the initial studies into the function of mda-7/IL-24 took place prior to its
classification as an interleukin, and utilized an adenoviral vector delivery system (Ad-
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mda7), thus expressing the protein intracellularly. IL-24 was found to activate multiple
apoptosis signaling molecules, some of which appeared to be cell-type specific. The
apoptosis induced by IL-24, which involves the caspase cascade (Saeki et aL, 2000),
occurred independently of p53, Ras, Rb, and p21 (Lebedeva et ah, 2003; Lebedeva et ah,
2005; Mhashilkar et ah, 2001; Su et ah, 2003), and was observed in a wide variety of
tumor cell types. While this antitumor activity was well-documented, the underlying
molecular mechanisms were not known. In 2002, Pataer et al found that IL-24 binds to
PKR (Protein Kinase R) in lung cancer cells, resulting in phosphorylation of both
molecules, and leading to cell death (Pataer et al., 2002; Pataer et al., 2005). Further
research demonstrated that this activation of PKR did not occur in some tumor cell types,
although the anti-tumor effects were the same (Chada et al., 2004). IL-24 has also been
found to activate c-jun and JNK in lung tumor cells (Kawabe et al., 2002; Yacoub et al.,
2003), and p38MAPK in melanoma cells (Sarkar et al., 2002). While p38MAPK and
JNK are both downstream targets of PKR, the connection of these pathways in the
function of IL-24 is uncertain, because PKR activation was not observed in melanoma
cells. Other molecular pathways modulated by IL-24 intracellularly include the balance
between proapoptotic Bax and anti-apoptotic Bcl-2/Bcl-XL (Cao et al., 2002; Lebedeva
et al., 2003), the Wnt and PI3K signaling pathway (Chada et al., 2005; Mhashilkar et al.,
2003), as well as induction of ROS and iNOS inhibition (Ekmekcioglu et al., 2003;
Lebedeva et al., 2003; Yacoub et al., 2003).
More recently, the activation of endoplasmic reticulum (ER) stress by
intracellular expression of IL-24 has been the focus of attention. Accumulation of
proteins that are unable to fold correctly in the ER activates the unfolded protein response
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(UPR) which allows the cell to deal with the protein excess (Schroder and Kaufman,
2005). If the cell is unable to resolve the accumulation of proteins, the UPR can induce
apoptosis by different mechanisms. Intrinsic apoptosis may be induced through
modulation of Bak and Bax (Zong et ah, 2003) or Bcl-2 (Hacki et al., 2000;
McCullough et al., 2001), involving cytochrome c (Hacki et al., 2000; Ito et al., 2001) or
independent of cytochrome c (Morishima et al., 2002; Rao et al., 2002). Additionally,
ER stress may trigger apoptosis through an extrinsic-like pathway involving the
transmembrane protein IRE1, which results in either JNK activation (Nishitoh et al.,
2002; Urano et al., 2000) or caspase 12 cleavage (Yoneda et al., 2001). IL-24 was found
to localize to the ER and Golgi, resulting in the induction of ER stress proteins (Sauane
et al., 2004; Sieger et al., 2004). Further research indicated that IL-24 interaction with ER
chaperone proteins BiP/GRP78 was essential but not sufficient for the induction of
apoptosis through the ER stress pathway (Gupta et al., 2006). A recent paper confirmed
that ER-stress and the UPR were responsible for IL-24 induced apoptosis independent of
the JAK/STAT pathway (Sauane et al., 2008). Preliminary speculation suggests that ER
stress may be the common upstream “trigger” for some of the diverse apoptotic pathways
activated by IL-24.

The cytokine functions of IL-24 are mediated through IL-20R1/IL20R2
and IL-22-R1/IL-20R2 receptors
The classification of IL-24 as a cytokine triggered interest in its receptor-mediated
activity, including speculation that secretion and receptor-mediated activity may be
responsible for the anti-tumor “bystander” activity observed in cells not directly infected
with the IL-24 expressing virus Ad-mda-7 (Chada et al., 2004; Lebedeva et al., 2007; Su
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et al., 2005). The receptors for IL-24 are associated with the JAK/STAT pathway, which
affects transcriptional regulation, particularly of genes involved in cell differentiation,
proliferation and apoptosis (Gopalkrishnan et al., 2004; Sauane et al., 2004). IL-24 is
indeed glycosylated and secreted (Lebedeva et al., 2005; Mhashilkar et al., 2001), and is
secreted even from cells infected with Ad-mda-7 (Chada et al., 2004; Sauane et al.,
2004). However, while the exogenous protein is cytotoxic to tumor cells, the mechanisms
are unclear. Binding to its receptors, IL-24 activates STATS, and to a lesser extent
STAT1 (Pamsh-Novak et al., 2002), but this activation isn’t essential for tumor cell
killing (Chada et al., 2005; Zheng et al., 2007). Further, the purified protein exerts its
cytotoxic activity regardless of the receptor status of the tumor cells (Lebedeva et al.,
2005).
Anti-tumor effects can be exerted through the immune system, in addition to
effects triggering apoptotic pathways. Investigation into the immune function of IL-24
found that unlike IL-10, which exhibits primarily immuno-suppressive Th2-type activity,
IL-24 is immunostimulatory. When applied to PBMCs in culture, IL-24 induced
activation and production of TNF-a, IL-1, IFN-y, IL-6 and GM-CSF (Caudell et al.,
2002). This immuno stimulatory function was confirmed in a clinical trial, which
observed an increase in these cytokines in the serum of patients who had received an
intratumoral injection of Ad-Mda-7 (Tong et al., 2005).

Alternative Splicing ofIL-24
Interleukin-24 consists of 7 exons and 6 introns (Huang et al., 2001), with three
different splice variants reported in the literature, two of which have been validated and
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deposited in the Ref Seq database (See figure 17 and 20). Isoform 1 contains all 7 exons
(NM_006850.2), while Isoform 2 lacks exons 3 and 5 (NM_181339.1). It was originally
described by Allen et al (Allen et ah, 2004), and is referred to as mda-7s. The authors
predicted that it heterodimerizes with full-length IL-24, but found no effect of mda-7s on
the kinetics of cell death induced by full-length IL-24. Expression analysis found mda-7s
in normal melanocytes, but reduced or absent in melanomas, leading these researchers to
suggest that loss of this splice variant is associated with tumor progression (Allen et ah,
2004). A second report by the same group identified splice variants of IL-24 lacking
either exon 3 or exon 5, but no functional analysis of these variants was conducted
(Allen et ah, 2005). A recent study of the mouse analog for IL-24 (FISP) found a novel
splice variant that lacks 29 nucleotides from the 5’ end of exon 4 (Sahoo et ah, 2008).
This set of results indicates that the variant (FISP-sp) dimerizes with the full-length
version, blocks its secretion, and inhibits the induction of apoptosis.

Purpose of this Study
Alternative mRNA splicing is an important field of study, and a great deal of
research is currently focused on understanding how this tightly controlled process is
modified in response to different circumstances. Altered splicing can affect the function
of a gene product in many ways, not only by changing its expression level, but also by
modifying the intracellular or extracellular location of the protein, changing the kinetics
of an enzyme, affecting the ability of the protein product to dimerize, or generating a
protein with a completely new function. Aberrant splicing is frequently associated with a
number of diseases including cancer. Because this aberrant splicing is widespread and the
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underlying mechanisms are not well understood, we examine one pathway in this
complex network of changes by asking the following questions: 1) How can an external
event modify the expression of a splice factor? We examine the regulation of SFRS6 by
p53 in response to DNA damage in chapter 2. 2) How does the silencing of SRp55
influence the splicing of its target gene, IL-24? This question is addressed in chapter 3.3)
How might the different splice isoforms of a target gene affect cell survival? In chapter 4,
we characterize five novel isoforms of IL-24, including their structure and effect on
cancer cell survival.
The research described in this study provides important insight into splicing
control by describing a model pathway for the regulation of expression for a specific
splice factor, how that splice factor affects the splicing of a specific gene product, and the
different effects that those splice variants can have on the cell.
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CHAPTER TWO
P53 BINDS DIRECTLY TO TWO REGIONS ON THE SPLICE FACTOR SFRS6
PROMOTER AND INHIBITS ITS EXPRESSION

Introduction
Alternative splicing of mRNA is increasingly seen as an important regulator of
cellular function. While the activity of the spliceosome is well understood, the
mechanism of splice site selection is less clearly defined. The core spliceosome consists
of five small nuclear ribonucleoproteins (snRNPs) that recognize consensus sequences at
the 3’ and 5’ ends of the intron (U1 and U2), bind an additional tri-snRNP (U4, U5 and
U6), and rearrange to excise the intronic mRNA. Additionally, enhancer and silencer
sequences are recognized by other splicing-associated proteins to help define the exon.
There are over 200 identified splicing factors, most of which belong to one of two
groups: the SR family and hnRNPs. These splice factors recognize and bind to weakly
conserved cis elements on the pre-mRNA (Black, 2003).
The SR family consists of 11 proteins, each of which have 1 or 2 N-terminal RNA
binding domains that interact with the pre-mRNA. They additionally contain an
arginine/serine rich C-terminal RS domain responsible for the protein-protein interactions
involved in recruiting additional splice factors during spliceosome assembly. SR proteins
play important roles in both regulated and constitutive splicing. The recognition of splice
sites by the SR proteins is somewhat degenerate, with overlapping and promiscuous
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sequence recognition that varies in a concentration-dependent and tissue-specific manner
(Graveley, 2000; Stamm, 2002).
The SFRS6 gene codes for SRp55, a protein in the SR family of splicing factors.
While many of the SR proteins have overlapping functions, SRp55 is notable for its
specific involvement in angiogenesis, which is particularly important in the field of
cancer biology. It is responsible for switching between pro- and anti-angiogenic isoforms
of VEGF (vascular endothelial growth factor) (Nowak et ah, 2008; Nowak et ah, 2010;
Qiu et al., 2009) and coagulation trigger TF (tissue factor). Our lab initially became
interested in SFRS6 because of its responsiveness to p53. Tumor suppressor p53 carries
out many of its effects through transcriptional regulation; it can function both as an
activator and repressor (Kannan et al., 2001). We previously reported that in cells
lacking p53, SFRS6 expression increased in response to DNA damage, while this increase
was not seen in cells with normal levels of p53 (Filippov et al., 2007; Filippov et al.,
2008). This led us to hypothesize that p53 was inhibiting SFRS6 expression, but the
mechanism for this inhibition was unknown. Our results were supported by a preliminary
bioinformatics analysis using a public microarray database that indicated that the
majority of the SR proteins have a tendency to be down-regulated as a result of p53 over
expression (Sbisa et al., 2007) (Table 1).
In this study, we performed experiments to confirm that p53 is inhibiting SFRS6
expression, and further analyzed the mechanism for this inhibition. We describe two p53
responsive elements on the promoter region of SFRS6 that are required for the inhibition
of this promoter by p53. Further, we establish that this inhibition involves direct binding
of p53 to the SFRS6 promoter.
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Figure 6. Cloning of promoter regions for SFRS6: Upper Panel: Promoters were cloned
into the pMetLuc reporter vector (Clontech) which is a reporter vector that produces
secreted luciferase. Lower Panel: The 5.5 kb promoter region of SFRS6. Smal and
Hindlll: Select restriction enzyme sites, RE: p53 response element, bent arrow: initiation
site.
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Materials and Methods
Cloning of Constructs
To study the activity and regulation of the SFRS6 promoter, we utilized the
pMetLuc vector (Clontech), a secreted luciferase reporter vector (Figure 6). Several
constructs were generated. First, 5.5 kb of the SFRS6 promoter was cloned into the
pMetLuc reporter vector (Figure 6). This 5.5 kb region is orthologous in humans and
mice, and is referred to as the “full-length” promoter. The construct is named pMetLucSFRS6. Additionally, we created deletion mutants for the SFRS6 promoter that eliminate
one (pMetLuc-577^5,<5ARE2) or both (pMetLuc-AFT^dAA) of the putative p53 REs in
order to determine whether these regions are responsive to p53 (Figure 7). pMetLucSFRS6 was cut with Hindlll and ligated back together to form pMetLuc-AF7?5'(5ARE2. In
order to generate a construct lacking both REs, pMetLuc-577/?5'dARE2 was cut with Smal
and ligated back together to generate pMeiLuc-SFRS6AA. Finally, a minimal promoter
construct was also created (pMetEuc-AE/^AdAXhoI) that retains the promoter elements
necessary to drive transcription, but lacks all of the upstream regulatory elements,
including both p53 REs (Figure 7).
Two p53 expressing constructs were utilized; the first is a constitutively active
p53 expressing plasmid (pc53-sn3) that has been frequently used in our laboratory and
others (Fujisawa et ah, 2003; Mikata et ah, 2002), and was originally constructed by
Baker et al (Baker et ah, 1990). Additionally, we generated a plasmid in which the p53
gene is under the control of a tet-on transactivator (pTet-on-p53). The gene is not
expressed unless doxycycline is present in the medium.
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Figure 7. Cloning of promoter regions for SFRS6. Several constructs have been created
in the pMetLuc reporter vector: Upper Panel: SFRS6 ARE2 was created from SFRS6 by
cutting with Hindlll to remove RE2, and ligating the ends back together. Middle Panel:
SFRS6 AA was created from SFRS6 ARE2 by cutting with Smal and ligating the ends
back together. Lower Panel: SFRS6 AXho, a minimal promoter was generated by cutting
with Xhol. It retains the promoter elements necessary to drive transcription, but lacks all
of the upstream regulatory elements, including both p53 REs.
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Bioinformatic Analysis
We utilized the p53FamTag database
(http://www2.ba.itb.cnr.it/P53TAG/index.php), a web-based utility that performs in silico
prediction of p53 responsive elements (Sbisa et ah, 2007). Searching the database for
hits in the promoter region of SFRS6 yielded 2 putative p53 REs, with the sequences
aggcatgtgccaccatgcccagctaatttt and agctttgttctttccttcaggcaggttggagtcttgctt.

Cell Lines and Cell Culture
A pair of cell lines derived from human colon cancer were obtained as a kind gift
from Dr. Bert Vogelstein (Bunz et al., 1998). These cells express (HCT116) or do not
express (HCT116p53-/-) p53, and were cultured in McCoy’s 5A medium (Invitrogen,
Carlsbad CA) supplemented with 10% fetal bovine serum (PAA Laboratories, Ontario,
Canada), penicillin (100 U/ml) and streptomycin (100 fig/ml) (Sigma-Aldrich). U20S
cells, derived from an osteosarcoma, were obtained from ATCC and cultured under the
same conditions.

Transient Transfections
Cells were plated to reach 70% confluency by the day of transfection. The
transfection mixture was prepared using TransIT-LTI (Mims Bio) at a ratio of 3 pL
reagent: 2 pg DNA in minimal cell culture medium, and allowed to stand for 20 minutes
at room temperature before adding to cell culture medium.
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Secreted Luciferase Assay
The pMetLuc reporter vector contains a gene for Metridia luciferase that is
secreted into the cell culture medum. Forty-eight hours after transfection, cell culture
media was replaced with fresh growth medium for four hours. 50 pi of medium from the
cell cultures was collected and transferred to a white 96 well plate. Clontech’s Ready-ToGlow Secreted Luciferase Reporter Assay was used to detect light emission according to
the manufacturer’s instructions. Light emission was read in a microplate reader.

Electrophoretic Mobility Shift Assay (EMSA)
A fluorescence-based electrophoretic mobility shift assay (EMSA) was utilized to
assess binding of p53 to the promoter in vitro. DNA oligonucleotides corresponding to
the desired regions of the SFRS6 promoter (RE1 (AGGCATGTGC CACCATGCCC
AGCTAATTTT), RE2, and an irrelevant region (See arrows in Lower Panel of Figure 6)
as well as a p53 consensus binding sequence, were designed. They were obtained from
Licor Biosciences with IRDye 700 or 800 infrared end-labeling. Oligonucleotides were
placed in a binding reaction with purified His-tagged p53 protein (Thermo Scientific)
according to the manufacturer’s instructions. The binding reaction was placed in the dark
at room temperature for 30 minutes, and then the reactions were separated in a 5% TBE
gel in a dark room. The fluorescent nucleotide migration was visualized in the gel using
the Odyssey Infrared Imaging System (Licor Biosciences).
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Chromatin Immunoprecipitation (CHIP)
HCT116 or HCT116p53-/- cells were fixed with formalin (Thermo Scientific) to
crosslink proteins bound to DNA. We used the ChIP-IT Express Chromatin
Immunoprecipitation Kit (Active Motif) according to the manufacturer’s instructions.
Briefly, cells were collected, the DNA was fragmented enzymatically, and IP was carried
out using antibodies directed against p53, or an irrelevant antibody (anti-HA). Antibodies
were bound to protein G-coated magnetic beads, and unbound proteins were removed in a
series of washes. Crosslinking was reversed, the proteins were digested, and real time
PCR was performed on the recovered DNA. Primers were designed to amplify RE1
(primer pair 1), RE2 (primer pair 2) and a region on the SFRS6 promoter not predicted to
be bound by p53 (primer pair 3) (See numbered arrows on Figure 6, Lower Panel).

Results
p53 Reduces SFRS6 Expression
Previous work in our laboratory had identified p53 as a negative regulator of the
splice factor SRp55, encoded by the SFRS6 gene. Specifically, we found that in response
to DNA damage, SRp55 levels were up-regulated in the absence of p53, but not in cells
expressing p53 normally (Filippov et al., 2007). This led us to analyze the promoter
region of SFRS6 to see if there were any known p53 binding domains. In fact, two
putative p53 responsive elements were found, and are hereafter referred to as RE1 and
RE2 (Figure 6, Lower Panel).
To confirm that p53 negatively regulates SFRS6 expression, cells expressing
(HCT116) or not expressing (HCT116p53-/-) p53 were transiently transfected with the
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Figure 8. Expression of SFRS6 is reduced with increased p53 expression: Cells
expressing or not expressing p53 were transiently transfected with the full-length SFRS6
promoter in the secreted luciferase vector, and co-transfected with increasing
concentrations of a p53 expressing plasmid, pc53SN3.
Forty-eight hours after
transfection, medium from the cell cultures was subjected to a secreted luciferase assay to
test for promoter activity. p53 expressing cells had too much endogenous p53 to be
affected by increasing exogenous p53, but p53-/- cells showed a decrease in promoter
activity with increasing concentrations of p53. For transfection normalization, cells were
co-transfected with green fluorescent protein (GFP). Data is expressed as relative light
units (RLU). * Indicates significantly lower luciferase expression (promoter activity)
with p53 transfection than without (p < 0.05).
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vector pMetLuc-SF.ftiStf, and co-transfected with various concentrations of the p53
expressing plasmid pp53SN3 or a vector control to determine the effect of p53 on the
promoters. Forty-eight hours after transfection, cell culture medium was replaced with
fresh growth medium for four hours. 50 pi of medium from the cell cultures was
collected and subjected to a secreted luciferase assay to determine whether the SFRS6
promoter was driving luciferase expression. In the p53 expressing cells, the promoter
activity remained low, despite the increasing concentrations of p53. However, in the cells
lacking p53, luciferase levels (and thus SFRS6 promoter activity) were approximately
three times higher, and decreased in a dose-dependent manner as p53 concentrations were
increased (Figure 8). Presumably, the endogenous levels of p53 in the HCT116 cells were
sufficient to inhibit the expression of SFRS6, while the effect of increasing p53
transfection could be observed in cells lacking endogenous p53.

Responsiveness of SFRS6 to p53 is Dependent on Putative
p53 Responsive Elements
Having confirmed that SFRS6 is negatively regulated by p53, we wanted to
investigate whether this effect was due to direct p53 binding to the promoter, or whether
the effect was through an intermediary protein interaction. Our initial approach was to
create deletion mutants that eliminated the putative REs where p53 was predicted to bind.
Additionally, to simplify the transfection procedure and reduce introduced error, a
plasmid construct was generated with p53 under the control of a tet-activated promoter
(pTet-on-TP53). This eliminated the need to transfect with a third vector control
construct in order to express different levels of p53 in our cells.
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Figure 9. Responsiveness of SFRS6 to p53 is dependent on putative p53 REs: HCT116
p53-/- cells were transiently transfected with our promoter constructs, and co-transfected
with a tet-activated p53 expressing plasmid, pTet-on-TP53, and treated or not treated
with 2 pg/ml doxycycline to activate the expression of p53. Forty-eight hours after
transfection, medium from the cell cultures was subjected to a secreted luciferase assay to
test for promoter activity. Upper Panel: The full-length pMetLuc-SFRSd promoter
(SFRS6) showed decreased activity with increasing concentrations of p53. The p53responsiveness of the pMetLuc-SFRSbARF^ promoter (577RiS'ddeltaRE2), lacking one of
the two putative p53 REs was reduced, but still statistically significant (p=0.025). In the
pMetLuc-AFRAdAA (SFRS6 deltadelta) and pMetLuc-AFRAdAXhoI (SFRS6 deltaXhoI)
constructs, lacking both p53 REs, there was no responsiveness to p53. * Indicates
significantly lower luciferase (and hence, promoter activity) in the dox containing
medium compared to the medium without dox. Lower Panel: Representative immunoblot
showing doxycycline induction of p53. Cells were transiently transfected with pTet-onTP53, and cultured in medium containing no doxycyline or 2 pg/ml doxycycline to
activate the expression of p53. Forty-eight hours after transfection, cells were lysed with
Laemmli buffer, and lysates were subjected to electrophoresis by SDS-PAGE. Proteins
were transferred to a PVDF membrane and probed with antibodies directed against p53.
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Cells lacking endogenous p53 (HCT116p53-/-) were transiently transfected with
one of the promoter constructs and the pTet-on-p53 plasmid. Parallel transfections were
treated or not treated with 2 pg/ml doxycycline (dox) to activate p53 expression. After 48
hours, the medium was replaced with fresh growth medium (with the same dox
concentration) for four hours. Medium was collected and subjected to analysis for
secreted luciferase. The results are shown in Figure 9. The full-length SFRS6 promoter
construct drives luciferase expression, but this activity is reduced by approximately half
when doxycycline is added to the medium to induce p53 expression. Dox induction of
p53 was validated by immunoblot (Figure 9, Lower Panel). The SFRS6 construct lacking
RE2 (pMetLuc-5,Fi?1S(5A2) still retained p53 responsiveness, but it was abrogated in
comparison to the full SFRS6 promoter. The construct lacking both RE 1 and RE2
(pMetEuc-SEftAbAA) lost all responsiveness to p53. Similarly, the minimal promoter
construct (pMetLuc-AF^AAAXhoI) had no p53 responsiveness.

Purified p53 Protein Binds to the Predicted p53 REs
on the SFRS6 Promoter in vitro
The results described above confirm that the p53 responsiveness of the SFRS6
promoter is dependent on the putative REs that were identified. Next, we wanted to
determine whether this p53 responsiveness is due to direct binding of p53 to the SFRS6
promoter, or whether the effect we had observed was due to indirect interactions. In order
to assess the direct binding of p53 to the SFRS6 REs in vitro, we utilized an
electrophoretic mobility shift assay (EMSA).
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Figure 10. Purified p53 protein binds to the putative p53 REs of SFRS6 in vitro: EMSA
was performed to determine if p53 binds to the putative REs in vitro. Upper Panel:
Fluorescently labeled, double stranded oligonucleotides corresponding to the two REs.
Lines below REs on SFRS6 promoter diagram represent location of oligonucleotide
sequences. DNA was incubated in a binding reaction for 30 minutes with different
dilutions of purified p53 protein. Lower Panel: Binding reactions were loaded into a gel
and separated by PAGE. (A) Oligonucleotides corresponding to the sequence of RE1 (B)
Oligonucleotides corresponding to the sequence of RE2 (C) As a positive control,
oligonucleotides corresponding to the sequence of a known p5 3-binding element from
p53AIPl were used, and the binding pattern corresponded to those of our REs.
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Fluorescently labeled oligonucleotides corresponding to RE1 and RE2 were
designed (Figure 10, Upper Panel). Additionally, fluorescently labeled oligonucleotides
corresponding to a consensus p53 binding domain were obtained. These oligonucleotides
were allowed to incubate in a binding reaction with purified p53 protein, and the reaction
mixture was subjected to electrophoresis to separate the free oligonucleotides from the
protein-bound oligonucleotides. The results are shown in Figure 10, Lower Panel. In lane
1 of each gel, no protein was added, and free oligonucleotides migrated to the bottom of
the gel during electrophoresis. In the remaining lanes, serial dilutions of purified p53
protein were added to the binding reaction. A concentration-dependent shift in migration
of the labeled oligonucleotides is seen with increased protein concentration, A similar
pattern is seen for both RE1 and RE2, as well as the p53 consensus sequence, confirming
that p53 was binding directly to these DNA sequences.

DNA Damage-Induced p53 Binds to the Predicted
REs on the SFRS6 Promoter in vivo
To confirm that the v5?>-SFRS6 binding was occurring in cells, and not just in an
isolated reaction mixture, we employed chromatin immunoprecipitation (ChIP). HCT116
cells were treated with the DNA damaging agent Mitomycin C (MMC) in order to
activate p53 expression. The cells were fixed, and nuclear extracts were isolated. DNA
was fragmented and either an antibody directed against p53 or an irrelevant control
antibody were used to pull down DNA bound by the p53 protein. Real-time PCR was
performed using primers designed to amplify the REs, or an irrelevant area on the SFRS6
promoter (Figure 11, Upper Panel). Background levels of amplification were subtracted
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Figure 11. Induced p53 binds to the predicted response elements on the SFRS6 promoter:
p53 binding to predicted REs was assessed by ChIP assay. HCT116 cells were treated
with Mitomycin C to induce p53 expression. Cells were fixed to crosslink protein to
DNA, the DNA was fragmented by sonication, and p53 was used to pull down bound
DNA. Crosslinking was reversed, and real time PCR was performed on the recovered
DNA. Upper Panel: PCR was carried out using primers designed to recognize the p53
response elements (Primer pairs 1 and 2) as well as a region on the SFRS6 promoter not
predicted to be bound by p53 (Primer pair 3), represented by arrows below diagram of
SFRS6 promoter. Lower Panel: Activated p53 bound to the predicted response elements
with a 6-fold (RE1) or 12-fold (RE2) increase in affinity when compared with a non RE
area on the promoter.
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out using the irrelevant antibody. PCR amplification for the 3rd primer pair was near
background, indicating no detectable p53 binding to this region. In contrast, amplification
of the two REs was increased 6-12 fold compared to background, indicating that p53
binds to both of these regions on the SFRS6 promoter (Figure 11, Lower Panel). Similar
results were seen in U20S cells (data not shown).
The results described above demonstrate that activated p53 binds directly to RE1
and RE2 on the SFRS6 promoter in cells. Next, we wanted to determine if baseline levels
of p53 (p53 present in the absence of a DNA-damaging insult) were also able to bind to
the REs in vivo. To answer this question, HCT116 cells were treated with MMC or left
untreated. ChIP was performed using p53 antibodies (and irrelevant antibodies to
eliminate background levels of non-specific binding). Real-time PCR was performed
using the same primer sets, and the results are shown in Figure 12. Our results
demonstrate that while we are consistently able to detect binding of activated p53 to both
REs, baseline p53 levels do not bind to the REs at a level that is detectable by ChIP.

Discussion
Alternative splicing is the focus of a large field of research, not only because of its
importance for expanding the proteome, but also for its many emerging roles in cancer
and disease and in the cellular response to stress. The carefully controlled splicing
modifications that are specific to tissue type, stress response and even cancer are
mediated by more than 200 different splicing factors, including the SR family of proteins.
These complex global splicing changes are not clearly understood. Our lab, however, was
one of the first to link an external event (DNA damage) with a change in the expression
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Figure 12. Baseline levels of p53 do not bind to the predicted response elements on the
SFRS6 promoter: p53 binding to predicted REs was assessed by ChIP assay. HCT116
cells were treated with Mitomycin C (MMC) to induce p53 expression, or left untreated.
Cells were fixed to crosslink protein to DNA, the DNA was fragmented by sonication,
and p53 was used to pull down bound DNA. Crosslinking was reversed, and real time
PCR was performed on the recovered DNA. While activated p53 (cells treated with
MMC) bound to the predicted REs as was shown in the previous figure, background
levels of p53 (untreated cells) did not bind to the REs at high enough levels to be
detectable by ChIP.
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of a splice factor (SFRS6) and a resultant change in the splicing of target genes (Filippov
et ah, 2007).
In this study, we have explored the mechanism by which p53 modifies the
expression of SFRS6. We found that p53, when activated by DNA damage, binds directly
to two responsive elements on the SFRS6 promoter and inhibits its expression. This is
particularly intriguing because of the role of p53 in the cell’s response to DNA damage,
which is so important that it has been called “the guardian of the genome” (Efeyan and
Serrano, 2007). However, despite (or perhaps because of) its importance in protecting the
cell from replicating damaged DNA, p53 mutations are common; less than 50% of human
cancers have a normally functioning p53 pathway (Hollstein et ah, 1991). In cells
withfunctional p53, the protein is activated in response to a variety of stresses, and it
activates the expression of a number of genes related to cell cycle arrest and apoptosis
(Efeyan and Serrano, 2007; Hofseth et ah, 2004; Pietsch et ah, 2008). It has been
observed that cells lacking p53 are still able to respond to stress by halting the cell cycle
or inducing apoptosis, but through alternative pathways. Presumably, there is some form
of cross-talk in the cell so that in cases where p53 is lacking, these other responses can be
initiated. One such alternative pathway involves ceramide (Bose et ah, 1995; Perry et
ah, 2000; Strum et ah, 1994; Tepper et ah, 1999). An additional p53-alternative pathway
involving modification of alternative splicing was suggested by our earlier research
(Filippov et ah, 2007; Filippov et ah, 2008), and was further elucidated in this study.
Following DNA damage, if p53 is present in the cell, it will bind to the REs on SFRS6
and prevent its up-regulation, and the p53 response to DNA damage will proceed
normally. However, in the absence of p53, SFRS6 is up-regulated in response to DNA
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damage, and splicing changes can be initiated in apoptosis-related genes, including IL-24,
Fas, and CD44 (Filippov et ah, 2007; Filippov et ah, 2008). The data described in this
chapter complements the existing literature and suggests a way that the cell can react
differently to stress depending on its p53 status. In the model that we have proposed, the
STT^b-mediated splicing response to DNA damage is a null pathway in cells with
normally functioning p53. It is only in the cases where the cell’s normal response
pathway is inactivated or deficient that this alternative damage response is initiated.
This pathway is presumably just one of many ways that the cell modifies its
splicing in response to stress. Global changes in alternative splicing have been described
in cancer (Skotheim and Nees, 2007; Venables, 2004); this aberrant splicing has even
been proposed as a “cancer biomarker” (Brinkman, 2004). Corresponding changes in
splice factor expression have also been reported in cancer (Skotheim and Nees, 2007).
The research described in this chapter provides just one example of a mechanism by
which these changes may be initiated within the cell.
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Abstract
Alternative splicing is an important source of protein diversity, and is an
established but not yet fully understood mechanism for gene regulation in higher
eukaryotes. Its regulation is governed by a variety of mechanisms, including variation in
the expression levels of splicing factors engaged in spliceosome formation. SRp55 is one
of the most ubiquitous splicing factors and one that can be up-regulated by DNA damage
in the absence of p53, and we had previously found that depletion of its activity increased
resistance to DNA damage in p53-dependant manner. To assess its influence on the
splicing patterns of genes involved in apoptosis, we performed splice-specific microarray
analysis of cells treated with siRNA specific for this gene. This analysis, backed by RTPCR verification, identified three genes, KSR1, ZAK and mda7/IL24, which are sensitive
to SRp55 depletion. We also analyzed the splice patterns of apoptosis-related genes in
p53-deficient U20S cells following treatment with the genotoxic drug mitomycin C.
This analysis revealed that DNA damage resulted in changes in splicing activity that
modified the splicing pattern of Fas, a key pro-apoptotic, p53-inducible death receptor.
Interestingly, this modification led to an enrichment of the anti-apoptotic soluble Fas
isoform, and this secreted isoform was detected in the medium surrounding cells
subjected to DNA damage. These findings show that modulation of splicing activity in
p53-deficient cells during the early response to sub-lethal DNA damage results in a
change in the splicing of target genes, thus modifying the cellular response to genotoxic
agents.
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Introduction
Genome-wide analyses of human mRNA transcripts have shown that more than
two thirds of multi-exon genes have alternatively spliced isoforms (Johnson et ah, 2003),
and it is generally acknowledged that alternative splicing (AS) is a constitutive part of
gene regulation in higher eukaryotes. However, in contrast to the well-established
mechanisms of transcriptional regulation, molecular mechanisms controlling AS events
are poorly understood.
AS patterns are known to be highly tissue- and cell-type specific, implying that
splicing regulation is under tight control. Splice site selection is controlled by formation
of the spliceosome, a riboprotein complex that consists of a diverse array of factors
including members of the SR and hnRNP families of proteins (Matlin et ah, 2005). The
decision by which the splice site is chosen is believed to be regulated by combinatorial
control of the effective concentration and activity of splicing factors assembled within the
spliceosome (Stamm, 2002). Alterations in splicing can therefore be achieved by
changing the expression levels, intracellular localization, and posttranslational
modifications of the constituent splicing factors.
The importance of AS in regulating gene expression is demonstrated by a growing
number of diseases caused by abnormal splicing patterns, including such well-studied
pathologies as cystic fibrosis and spinal muscular atrophy (for review, see (Novoyatleva
et ah, 2006)). Studies of AS in cancer cells have also revealed that regulation of splicing
is significantly altered during tumorigenesis, and expression of certain cancer-specific
isoforms correlates with cancer progression (reviewed by (Skotheim and Nees, 2007)).
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Although the connection between disregulation of splicing activity and tumorigenesis is
clearly established, the mechanisms governing this process have not yet been identified.
One of the reasons for our poor understanding of AS regulation is the absence of a
reliable model system that is able to modify splicing in response to external stimuli.
There are a few examples showing that cellular stress, including temperature, osmotic
shock and DNA damage by UVC irradiation, can change the splicing patterns of certain
genes (Stamm, 2002). However, the precise regulatory mechanism of these splicing
modifications is not known.
Recently, we found that immediately following the application of a sub-lethal
concentration of a DNA damaging agent, p53-deficient cells activate AS activity by
transiently increasing expression of a number of SR proteins, including SRp55 (Filippov
et ah, 2007). Discovery of this transient splicing activation prompted us to search for
possible gene targets of this increased alternative splicing. Initially, we tested genes
known for their sensitivity to splicing factors that belong to the SR protein family. This
approach allowed us to identify the CD44 receptor as a target of increased splicing
activity in p53 deficient cells, and to demonstrate that increased expression of SRp55 was
necessary for its AS. To perform a more thorough and unbiased search for the targets of
changed splicing activity following DNA damage, we decided to analyze changes in
RNA splicing using a splicing microarray approach in two complementary comparisons.
In the first, we compared the splice patterns of apoptosis-related genes in cells with and
without a knock-down of SRp55 splicing factor activity, as SRp55 had been identified as
a factor whose expression and activity increased following DNA damage. Microarray
analysis followed by RT-PCR validation revealed that at least three apoptosis-related
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genes require SRp55 activity for proper splicing. In the second, we compared the splice
patterns of apoptosis-related genes in cells treated and not treated with the DNA
damaging agent mitomycin C. In this set of experiments, we found that p53-deficient
cells modulate their response to DNA damage by shifting the splice pattern of the Fas
gene such that the soluble, pro-survival variant is favored over the membrane-bound, proapoptotic isoform. Together, these observations demonstrate that cells can respond to
external stressors by directly regulating the expression of specific splicing factors,
thereby changing the splicing profile of target genes.

Materials and Methods
Cell Lines and Cell Culture
U20S cells, derived from a human osteosarcoma, were obtained from the ATCC
(Manassas, VA). They were cultured in McCoy’s 5A medium (Invitrogen, Carlsbad,
CA) supplemented to contain 10% fetal bovine serum (Invitrogen, Carlsbad, CA),
penicillin (100 pg/ml) and streptomycin (100 mg/ml) (Sigma, St. Louis, MO).
Construction of the pHA-E6S and pHA-E6AS plasmids, which respectively contain
either the sense or the antisense versions of HA-tagged E6 under the control of the CMV
promoter, and establishment of the U20SE64b and U20SE6AS cell lines by stable
transfection with these plasmids have been described previously (Filippova et ah, 2002).
Construction and characterization of the Tet-Off U20SE6tet24 cell line, in which E6
expression is regulated by the presence or absence of doxycycline, is described in
(Filippova et ah, 2004).
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Cell Survival and p53 Analysis
Cell survival analysis was performed using the MTT test (Filippova et al., 2002),
and the p53 ELISA was conducted as described previously (Filippova and DuerksenHughes, 2003).

Semi-quantitative RT-PCR
Reverse transcriptase - polymerase chain reaction (RT-PCR) analysis was used to
estimate transcript levels in total RNA samples isolated from cell cultures. 10 pg of total
RNA was used as a template for cDNA synthesis with Superscript III reverse
transcriptase and an oligo(dT) primer according to the manufacturer’s instructions
(Invitrogene, Carlsbad, CA). The cDNA obtained was normalized by PCR with primers
specific to cofilinl (CFL1). Serial dilutions of the normalized cDNA samples were used
to find the linear range of amplification for gene-specific DNA fragments. PCR was
performed at 94°C for 30 s, at 57°C for 30 s, and at 72°C for 1 min for 35 cycles using
Taq DNA polymerase and the recommended protocol (NEB, Beverly, MA). The
following sets of primers were used for RT-PCR analysis to detect expression of the
ATF3 gene: AT GAT GCTT C AAC ACCC AGGC and TTAGCTCTGCAATGTTCCTTC;
CASP gene: GAAGAAAG AGCTGAAC ATT CT GAA and
GAG AT GATGGAAAGC AGT GAAT; CFL1 gene; CCTTCCCAAACTGCTTTTGAT
and CTGGTCCTGCTTCCATGAGTA; Fas isoforms:
GAC ATGGCTTAG AAGT GGAAA and TTAGT GTC AT GACT CC AGC AA; KSR1-1
isoform: CTGGAGAAACTTCCCAAGCTGAAC and
AAAGAAGTAGCCTCGAGAGAGACG ; KSR1-2 isoform:
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CT GGAGAAACTTCCC AAGCTG AAC and CCA ACAGT CT GAATCTAGGACGTG ;
CUTL1 gene: TAACTCTTACAGCTTTGCCTTG and
GGAATCCAAACTAGTGTGTTTAGA; ZAK (a isoform):
CTTTAAGGAGCAGGAGCTTAAA and ATCT GC ATCCCAGAATGC AT ; ZAK (b
isoform): CTTTAAGGAGCAGGAGCTTAAA and
TGAGTCCTTAATTAGTGGTGGG; SFRS6 gene: C AGGT CGAGTT CCAGAGATTA
and TCAAACTGCAATTTCAACTCA; and mda7/IL24 gene:
CAGCCCTCAAGCATCACTTACA and TGCTCTCCGGAATAGCAGAAAC.

siRNA Inhibition of SFRS6 Gene Expression
Cells were transfected with pre-designed small interfering (si) RNAs for the
human SFRS6 gene obtained from Santa Cruz Biotechnology (sc-4418), or with control
siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) using the siRNA transfection kit as
recommended by the manufacturer (Santa Cruz Biotechnology, Santa Cruz, CA). To
obtain different levels of silencing of the SFRS6 gene, two concentrations of siRNA were
used: 0.5 pg and 0.25 pg per 6-well plate. After 48 hrs of incubation, the silencing effect
was evaluated by RT-PCR analysis as described above.

RNA Extraction and Splice Array Data Collection
Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA) and
additionally purified using the RNeasy kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. RNA samples for the siRNA inhibition experiment were
analyzed by RT-PCR to verify successful silencing of SFRS6 gene expression prior to
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splice array analysis. The splice array analysis was performed at the facilities of ExonHit
Therapeutics (ExonHit Therapeutics, Gaitherburg, MD) using the Human Apoptosis
SpliceArrays and employing a technical dye-swap.

Splice Array Data Analysis
Initial data analyses were performed using the SpliceAnalysis Tool supplied by
ExonHit Therapeutics as well as with Bioconductor. The Bioconductor version used
included the limmaGUI software package for differential expression analysis as
developed for two-color microarrays (Wettenhall and Smyth, 2004). The splice events
that contained probes with the highest statistical B values were further analyzed to
determine whether the ratios of probe hybridization outputs for probes specific to a splice
variant were in agreement with the changes of probes specific for the reference RNA
transcript, as previously described (Heinzen et ah, 2007).

Collection of the Cell Medium, Soluble Fas ELISA,
Immunoprecipitation and Western blot Analysis
Confluent cells were exposed to 2 pg/ml mitomycin C (Roche, Indianapolis, IN)
for 5 hrs, then the medium was collected and cleared by centrifugation. The
concentration of soluble Fas in medium from treated and untreated cell cultures was
estimated using a sCD95(AP01/Fas) ELISA kit (Cell Sciences, Canton, Massachusetts).
To perform immunoprecipitations, the medium were first concentrated from 4 ml to 1 ml
using Centricon centrifugal filtration through a YM-3 membrane (Millipore, Billerica,
MA). Concentrated medium were incubated with agarose-conjugated Fas monoclonal
antibodies (sc-8009, Santa Cruz Biotechnology, Santa Cruz, CA) for 16 hrs at 4°C and
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washed 3 times with the washing buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 01%
NP-40, ImM EDTA, 1 mM DTT). The precipitates were fractionated by 10% SDSPAGE and immunoblotting was performed as described previously (Filippova et ah,
2005). Fas protein was detected using rabbit polyclonal Fas antibodies (sc-714, Santa
Cruz Biotechnology, Santa Cruz, CA).

Results
The SRp55 contribution to the DNA damage response is p53-dependent
As we have previously shown, DNA damage activates AS activity in the HPV16
E6-expressing U20S cell line U20SE64b, with this activity peaking 5 hrs following drug
treatment. Furthermore, we found that this activation depends on p53, which is
efficiently degraded in the presence of E6 (Filippov et ah, 2007). The activation of AS
activity was due, at least in part, to an up-regulation in transcription of the SFRS6 gene,
leading to an increase in protein expression of the SRp55 splicing factor encoded by that
gene. Semi-quantitative RT-PCR showed that the increase in SFRS6 gene expression is
transient during DNA damage caused by mitomycin C treatment, such that after the
observed increase at 5 hrs, expression returns to its basal level by 10 hrs. This is in
contrast to the continued up-regulation of the transcriptional factor ATF3, as well as the
down-regulation of the transcriptional factor CUTE in the same RNA samples (Figure
13A, left panel). The up-regulation of SRp55 following DNA damage in cells lacking
p53 can also be demonstrated at the protein level (Figure 13 A, right panel).
These observations, as well as our previous observation that knock-down of
SFRS6 (encoding SRp55) by siRNA in cells lacking p53 led to increased viability
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Figure 13. Characterization of RNA samples subjected to SpliceArray™ analysis and effect
of SRp55 silencing on cell survival. A. Left panel: Level of ATF3, CUTL, SFRS6, and'
CFL1 transcripts in U20SE64b cells treated with 2 pg/ml mitomycin C for 5 and 10 hrs as
determined by RT-PCR analysis. Right panel: The SRp55 protein encoded by the SFRS6
gene has elevated expression levels in U20SE64b cells after incubation with mitomycin C
(2 pg/ml) for 5 hrs, but not in the control U20SAS cells (right panel). Lanes 1 and 3 show
lysates of untreated U20SAS and U20SE64b cells, and lanes 2 and 4 show lysates of
U20SAS and U20SE64b cells treated with 2 pg/ml mitomycin C for 5 hrs, respectively.
The levels of splicing factors were determined by immunoblotting with monoclonal
antibody 1H4 (ATCC, Manassas, VA). (3-Actin antibodies were used for re-blotting to
verify uniformity of sample loading. B. Left panel: Depletion of doxycycline (-Dox) in the
medium effectively decreases p53 levels in the Tet-Off U20SE6tet24 cell line but not in
control U20SAS cells. U20SAS or Tet-Off U20SE6 cells, grown in the presence or
absence of 10 ng/ml Dox, were lysed and the lysates analyzed for p53 by ELISA. Right
panel: Sensitivity of SRp55-depleted cells to mitomycin C treatment depends on the level of
p53. U20StetE624 cells, maintained in the presence of three concentrations of doxycycline,
were transfected with SRp55 or scrambled siRNAs, then subjected to DNA damage by
treatment with 4 pg/ml mitomycin C for 24 hrs. Viable cells were quantified using the MTT
assay, and the differences between SRp55 silenced and control cells were compared by
subtracting the number of viable cells in control scrambled siRNA samples from the number
of surviving cells transfected with SRp55 siRNA. Means from triplicate measurements are
shown, with the error bars representing the standard deviation. C. Left panel: Treatment of
U20S cells with 5T7?,Sd-specific siRNA effectively decreases the SFRS6 mRNA level. The
level of SFRS6 mRNA was determined by RT-PCR and normalized against expression
levels of the CFL1 gene. Right panel: Inhibition by siRNA leads to a decrease in the level
of the SRp55 protein. Immunoblot of protein lysates isolated from control U20S cells
(CNTRL) and U20S cells transfected with SFRS6 siRNA (siRNA). The p-actin antibodies
were used to verify uniformity of sample loading.
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following DNA damage (Filippov et al., 2007), led to the prediction that the ability of
SRp55 to affect cell viability following DNA damage would be dependant on the
presence, and possibly the amount, of p53. To test this prediction, we employed an
approach utilizing siRNA-mediated SRp55 silencing (Filippov et ah, 2007) in cells
where the levels of E6 expression could be controlled by changing the level of
doxycycline present in the medium, the Tet-Off U20SE6 cells (Filippova et ah, 2004).
To confirm that the level of biologically active E6 could indeed be controlled by the level
of doxycycline, we compared p53 levels by ELISA in mitomycin C-treated control
U20SAS cells that do not express E6, as well as in Tet-Off U20SE6 cells either
expressing E6 at a high level (-Dox) or when E6 expression is inhibited by the antibiotic
(+Dox). As expected, a high level of E6 expression caused rapid p53 degradation, while
repression of E6 expression by Dox almost completely restored p53 to the level observed
in the control U20SAS cells (Figure 13B, left panel).
We then asked whether manipulating the level of p53 in Tet-Off U20SE6 cells
would affect the ability of SRp55 to modulate biological activities such as cell survival
following DNA damage. To address this question, Tet-Off U20SE6 cells were
transfected with either SRp5 5-specific or control scrambled siRNA and incubated in the
presence of three different concentrations of Dox. After 24 hr treatment with mitomycin
C, these cells were evaluated for viability using the MTT assay. Comparison of survival
rates of Tet-Off U20SE6 cells with depleted SRp55 expression due to siRNA inhibition
versus the control cells showed a clear dependency on the concentration of Dox in
medium, such that the ability of siRNA directed against SFRS6 to impact survival was
greatest in the absence of p53 (Fig. 9B, right panel). This demonstrates that in the
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absence of p53, the activity of at least one splicing factor, SRp55, is capable of
interfering with the cellular response to mitomycin C treatment. The most plausible
mechanism for this interference may be an alteration in the splicing patterns of target
genes.

Splice Array Analysis Identified Changes in Splicing Events
To identify candidate target genes, we compared splicing events in apoptosisrelated genes in two pairs of RNA samples using ExonHit SpliceArray TM microarrays.
In the first analysis, we monitored changes in the splicing of apoptosis-related genes in
U20S cells that were sensitive to depletion of SRp55 splicing factor activity. U20S cells
were transfected with siRNA directed against SFRS6 mRNA, encoding the SRp55
protein, or with control scrambled siRNA oligonucleotides. These cells were then
examined for the resulting down-regulation of the SFRS6 message and SRp55 protein
(Figure 13C), and analyzed for their expression of splice variants of apoptosis-related
human genes using ExonHit splice arrays. In the second comparison, we compared RNA
isolated from U20SE64b cells treated with 2 pg/ml mitomycin C for 5 hrs with RNA
isolated from untreated cells. This analysis allowed us to identify candidate genes with
splice patterns that could be affected by increased AS activity induced by DNA damage.
The raw hybridization data were then processed using tools developed by
Bioconductor for the analysis of two-color microarrays in order to yield lists of probes
with the highest statistical B values. These B-statistics evaluate the probability that
sequences hybridizing to a particular probe are differentially expressed. Since for each of
the two experiments, siRNA silencing and mitomycin C treatment, only one technical
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repeat was subjected to splice array hybridization, the B values for differential
hybridization of array probes were considerably low, and were considered only as an
indication that hybridization to a probe might reflect splicing changes. Next, we
analyzed selected splicing events in which probes with the highest B values were
involved. Each splicing event is represented on the array by up to six probes that can
quantify the presence of purely exonic sequences as well as exon-exon junctions in
analyzed RNA samples. In situations where an actual shift in the splicing patterns have
occurred, an increase in the binding of probes for a particular splice variant should be
accompanied by an increase in the ratio for the binding of its specific probe(s), as well as
a decrease in the binding for probes specific to the reference transcript (Heinzen et ah,
2007). Using this rationale, we selected four candidate splicing events, designed primers
specific for these events and performed subsequent RT-PCR analysis.

Depletion of SRp55 Levels Change the Isoform Ratios for
the KSR1 and ZAK Kinases
The effectiveness of the approach we used for verification of the splice array data
is supported by the analysis of two splicing events. In the first splicing event, microarray
hybridization showed coordinated changes in the hybridization of three probes specific
for AS of the last exon of the KSR1 gene, encoding the Kinase Suppressor of Rasl. As
shown on the scheme, these three probes, A5, B and C, monitor splicing of an alternative
acceptor site located within exon 21 of the KSR1 gene (Figure 14A, left panel). While
the 5’ probe A5 and the 3’ probe B should be present in both isoforms, probe C
represents the junction of exon 20 with the alternative acceptor site of exon 21.
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Figure 14. Splicing patterns of KSR1, ZAK and mda7/IL24 genes are sensitive to SRp55
expression. A. Schemes of the regions of the KSR1 and ZAK gene structures involved in
the tested AS events. Arrows F, R1 and R2 show the primers used for RT-PCR analyses
for each of these genes. Rectangles A5, B, C, and E show localization of the
SpliceArray™ probes. B. Left panel: Increased expression of the KSR1 isoform with
truncated exon 21 (KSR1-2) in SRp55-depleted U20S cells. The graph shows
quantification of the ratio between KSR1 isoforms, as recognized by primers F+Rl
(KSR1-1) and F+R2 (KSR1-2) in U20S cells with different levels of SRp55 expression.
Right panel: Changes in the splicing of the ZAK gene in SRp55-depleted U20S cells.
The graph shows quantification of the ratio between the two ZAK isoforms, as
recognized by primers F+Rl (p isoform) and F+R2 (a isoform) in U20S cells with
different levels of SRp55 expression. Two lower panels show RT-PCR analysis of
SFRS6 expression in these RNA samples isolated from U20S cells treated with
scrambled siRNA (Control), 0.25 pg or 0.5 pg SRFS6 specific siRNA (sil and si2,
respectively). C. Silencing of SRp55 expression by specific siRNA up-regulates the
abundance of the isoform represented by a 319 bp band in RT-PCR analysis using the
primers designated by arrows F and R. D. The amount of the SRp55-sensitive isoform is
proportional to the levels of silencing of SRp55. U20S cells were treated with scrambled
siRNA (CNTRL), 0.25 pg or 0.5 pg SRFS6 specific siRNA (sil and si2, respectively) to
decrease SRp55 expression gradually. Isolated RNA was subjected to RT-PCR analysis.
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The second example shows AS of the ZAK gene, a member of the MAPKKK
family of signal transduction kinases. In one alternative variant of the gene, exon 11 is
spliced to alternative exon 12A, which can be monitored by exon specific probe B and
junction-specific probe C (Figure 14A, right panel). This splice variant is a truncated
version of the gene that produces its p isoform (Gotoh et ah, 2001). Probe E for this
splice event is specific for the junction of exon 11 to exon 12B that represents the a
isoform of the gene, while probe A5 is common for both of the isoforms (Figure 14 A,
right panel).
To examine these two splicing events, qRT-PCR analysis was performed using
primers able to distinguish between the isoforms of the KSR1 and ZAK genes affected by
these splicing events. The levels of these isoforms were measured in samples of RNA
isolated from cells transfected with scrambled siRNA (Control), 0.25 pg of siRNA
specific for SRp55 (sil), and 0.5 pg of siRNA specific for SRp55 (si2). This allowed us
to manipulate the degree of gene silencing, as shown in Figure 14B (lower panels).
Calculation of the ratios between the two KSR1 isoforms in cells with different levels of
SRp55 silencing showed that reduced activity of the splicing factor led to a dosedependent increase of the KSR1 isoform with the truncated exon 21 (Figure 14B, left
panel). With regards to the ZAK gene, the qRT-PCR data showed that its expression in
control cells is predominantly of the p isoform. Quantification of the ZAK isoforms in
the silenced and untreated RNA samples did show some increase in the a splice variant in
SRp55 depleted cells (Figure 14B, right panel). However, we did not observe a strong
correlation between the degree of SRp55 silencing and changes in the isoform ratio. This
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observation may be an indication that regulation of this splicing event is quite complex
and that other factors may be involved.

Inclusion of Exons 2 and 3 of mRNA from mda7/IL24
Requires SRp55 Activity
The mda7/IL24 gene encodes a cytokine in the IL10 family that has been
demonstrated to be a potent tumor suppressor (Gupta et ah, 2006). This gene consists of
seven exons and currently has two isoforms deposited in the RefSeq database. Two
microarray probes for this gene showed a significantly changed signal ratio in the
siSRp55 experiment. RT-PCR expression analysis of this gene in U20S cells using a
primer set that covers the entire transcript showed that its pre-mRNA undergoes
extensive and varied splicing in U20S cells, yielding at least 4 distinguishable isoforms
(Figure 14C). Comparison of the splicing patterns of mda7/IL24 transcripts in control
and siRNA treated cells confirmed the splice microarray data, indicating that regulation
of splicing for at least one isoform of this gene is sensitive to silencing of the SRp55
splicing factor. Depletion of SRp55 splicing activity resulted in a substantial increase of
the isoform represented in RT-PCR by a 319 bp fragment (Figure 14C). Moreover, we
have found that the increase in this isoform is proportional to the decrease in the level of
SRp55 in treated cells (Figure 14D). Sequencing of this fragment revealed that this is the
annotated isoform 2 that lacks exons 2 and 3.
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Mitomycin C Treatment of E6 Expressing Cells Induces
Expression of Soluble Fas
The microarray hybridization of RNA samples isolated from U20SE64b cells
treated with 2 pg/ml mitomycin C for 5 hours produced considerably fewer probes with
significant changes in the signal probe ratio as compared to the siRNA silencing
experiment. One of the probes from this list belonged to a sequence specific to the Fas
receptor. Fas (CD95) receptor is a member of the TNF-Receptor superfamily that is
activated by binding to Fas ligand. It then transduces a pro-apoptotic signal into the cell
by formation of a death-inducing signaling complex (DISC) (Thorburn, 2004). To
monitor splicing of the Fas gene, we used primers designed to distinguish between the
soluble and membrane-bound forms of the message (Figure 15 A). In addition to the
expected membrane-bound form, we found detectable amounts of the soluble Fas (sFas)
isoform in both untreated U20SE6AS and U20SE64b cells under conditions where a
high number of amplification cycles were used (Figure 15B, upper panel). These results
also demonstrated that there is an increased amount of the sFas isoform following five
hours of mitomycin C treatment in the U20SE64b cells. To further explore this, semiquantitative RT-PCR using fewer replication cycles was performed (Figure 15B, lower
panel). In this experiment, we were able to detect this transcript variant only following 5
hrs of treatment, and only in the U20SE64b cells. Finally, following 5 hrs of treatment
of the U20SE64b cells, the combined density of both bands, representing the membrane
and soluble variants of the gene, was approximately equal (1.04) to the density of the Fas
gene in untreated cells, and its expression was split between these isoform in a 4:1 ratio
(Figure 15B). This suggests that the gene itself has not been up-regulated, although the
regulation of its splicing pattern has changed.
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Figure 15. Mitomycin C treatment induces up-regulation of Fas gene expression in
U20SE6AS cells and changes its splicing pattern in U20SE64b cells. A. Scheme of
alternative splicing of the Fas gene.
Skipping exon 6, which codes for the
transmembrane domain of the receptor, leads to expression of the soluble isoform (S),
while retention of the exon produces membrane bound receptor (R). Two arrows (F and
R) show the primers used to distinguish between these isoforms. B. Time course oiFas
gene expression during mitomycin C (2 mg/ml) treatment by RT-PCR analysis. The
CFL1 gene was used as a control. The ratio of the RT-PCR Fas R isoform bands to
control (0 hrs of drug treatment) is shown between the panels, with the density of the S
isoform for the U20SE64b cells after 5 hrs of treatment noted separately. C. Detection
of soluble Fas in cell culture medium. The concentration of soluble Fas protein secreted
into the medium was estimated by ELISA in medium collected from U20SE6AS and
U20SE64b cells untreated and treated with mitomycin C (MMC) (2 mg/ml) for 5 hrs.
Means from triplicate measurements are shown, with the error bars representing the
standard deviation. D. Immunoprecipitation analysis of medium collected from treated
and untreated U20SE64b cell cultures. Lane 1 - Fas immunoprecipitation of medium
from untreated U20SE64b cells. Lane 2 - Fas immunoprecipitation of medium from
U20SE64b cells treated with 2 mg/ml mitomycin C for 5 hrs. Lane 3 - U20SE64b
lysate.
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This increase in message coding for the sFas isoform was accompanied by the
secretion of this form of the protein into the cell medium, as detected by ELISA. Both
the p53-expressing U20SE6AS control cells and the p53-deficient U20SE64b cells were
treated with 2 pg/ml mitomycin C for 5 hours. The media were collected and subjected
to ELISA analysis for the presence of sFas protein. Medium from the control treated
anduntreated cells as well as the untreated U20SE64b cells did not contain detectable
amounts of sFas protein in any of the analyzed samples. The only samples that contained
detectable levels (the minimum detectable dose is 47 pg/ml) of the protein were from
medium collected from mitomycin C treated U20SE64b cells (Figure 15C). To confirm
the release of sFas into the medium by mitomycin C treated U20SE64b cells, we
immunoprecipitated this protein from the collected medium using agarose conjugated Fas
antibodies, and then performed an immunoblot analysis. This analysis showed that while
medium from untreated cells contained a trace amount of Fas, the medium collected from
the drug-treated cells contained a much higher level of this isoform of this protein (Figure
15D).

Discussion
Our discovery that AS activity is activated in p53-deficient cells treated with a
sub-lethal dose of a DNA damaging agent prompted us to search for genes that could be
affected by changes in splicing regulation. A search for possible targets among genes
that were known to be sensitive to the splicing activity of SR proteins allowed us to
identify such a target gene of this splicing activation, the CD44 receptor (Filippov et ah,
2007). Identification of such a target gene encouraged us to search for other possible
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targets using a more systematic approach. Currently, genome-wide analysis of AS using
microarray technology is considered the most comprehensive approach for identification
and quantification of splice events. Splicing microarray technology enables the
acquisition of a high resolution, exon-level snapshot of the population of RNA
transcripts. While it is potentially a very powerful tool for transcriptional studies, splice
microarray technology is still under development and a number of challenges remain.
In this report, we describe our use of splice microarray technology to analyze
splice events in two cellular systems. In the first system, splicing changes were analyzed
in cells where the splicing factor SRp55 had been depleted by siRNA. In the second
system, we identified splicing changes that occurred in p53-deficient cells that were
treated with a sub-lethal dose of a DNA damaging agent. The results obtained in both
experiments provided partial, rather than complete data on global splice changes for
several reasons. First, the number of genes tested was only 609, as the SpliceArray chips
we used covered a pool that contained only apoptosis-related genes. Secondly, only one
technical repeat was used for each experiment, which reduced the quality of statistical
data obtained. Third, the tools used for statistical processing of hybridization data were
somewhat limited and are still under development. Further development of microarray
technology will certainly provide a more comprehensive picture of splicing changes in
both tested systems. However, despite these limitations, we were able to identify several
splicing targets using this approach.
SRp55 belongs to the family of arginine/serine-rich splicing factors and is
involved in both constitutive and alternative splicing. Though its role in constitutive
splicing is believed to be redundant, its function was found to be essential for Drosophila
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development, since its mutation is lethal (Hoffman and Lis, 2000). A global analysis of
all annotated splicing events that generate the 8315 alternatively spliced RNAs in
Drosophila revealed that silencing of SRp55 by siRNA directly affected 107 events
(Blanchette et ah, 2005). This confirmed that while it may be redundant for constitutive
splicing, Drosophila SRp55 is required for regulation of several splicing events. Our
observation that depletion of SRp55 activity increases cellular resistance to DNA damage
in a p53-dependant manner (Figure 13B, right panel) suggests that in humans this
splicing factor may be required for splicing regulation of some genes engaged in the p53independent response to DNA damage. To further examine this possibility, we compared
normal gene splice patterns in human osteosarcoma U20S cells with the patterns seen in
cells depleted of SRp55 activity by siRNA. Analysis of the microarray data, coupled
with RT-PCR validation, showed that of the 609 genes present on the chip, at least three:
KSR1, ZAK and mda7/IL24, are sensitive to SRp55 activity during their splicing.
Microarray data pointed to possible SRp55 sensitive modifications in the splicing
of two kinases: KSR1 and ZAK (Figure 14A). RT-PCR analysis of these events
presented compelling data that SRp55 participates in regulation of splicing of the last
exon of the KSR1 gene. Depletion of this splicing factor caused a decrease in utilization
of the full-length exon 21, making the splice acceptor site located within exon 21 more
preferable (Figure 14B). RT-PCR data also showed that depletion of SRp55 caused less
dramatic changes in the regulation of the ratio between the a and (3 ZAK isoforms.
Though siRNA silencing led to an increase of the a isoform by as much as 2-fold, the
absence of a direct correlation between SRp55 activity and the isoform ratio may be due
to the involvement of other splicing factors in the regulation of this splicing event.
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Interestingly, while alteration of KSR1 splicing affects only the S’-UTR region of the
gene, changes in ZAK splicing directly affect the coding region, potentially modifying
one or more functions of the protein. RT-PCR analysis also confirmed SRp55
involvement in splicing of the mda7/IL24 gene (Figure 14C, D). In this case, splicing
factor depletion led to the generation of isoform 2, in which exons 2 and 3 have been
excluded. Identification of these SRp55 sensitive splicing events indicates that, as in the
case of its Drosophila homologue, human SRp55 is required for certain splicing events,
and other splicing factors cannot completely substitute for its activity.
Microarray analysis of splicing in p53-deficient U20SE64b cells treated with the
DNA damaging drug mitomycin C identified changes in splicing of the Fas gene. The
Fas receptor is one of the key inducers of apoptosis in response to a variety of stresses,
including DNA damage (Sharma et ah, 2000). It encodes a transmembrane member of
the TNF receptor superfamily that effectively mediates apoptosis after binding to its
ligand (FasL) (Krammer, 2000). Fas can be up-regulated by p53, and it is generally
believed that this p53-dependent induction during the DNA damage response sensitizes
cells to Fas mediated apoptosis and toxicity (Friesen et al., 1996). Consistent with this
idea, we also observed an up-regulation of Fas in p53-expressing U20SE6AS cells
(Figure 15B). However, in the absence of p53, rather than an overall up-regulation of Fas
expression, we observed increased expression of the soluble Fas isoform (Figure 15B).
Exclusion of exon 6, which encodes the transmembrane region of the receptor molecule,
produces a soluble isoform of the Fas gene that is unable to transmit the apoptotic signal
(Figure 15A) (Cheng et al., 1994). Instead, this soluble isoform binds to ligand in the
surrounding medium, thus preventing the ligand from binding membrane-bound Fas and
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protecting cells from apoptosis. This increased level of sFas RNA transcript was also
accompanied by the appearance of a detectable amount of soluble Fas protein in the
medium of U20SE64b cells treated with mitomycin C (Figure 15C and 15D). Based on
these data, one may propose a model of how cells modify their response to DNA damage
by modulation of splicing regulation. Activation of the p53 pathway following DNA
damage increases the number of Fas molecules on the cell surface, thus making cells
more susceptible to Fas-mediated apoptosis (Figure 16A, left side). In the absence of the
proper p53 response to DNA damage, however, cells not only fail to up-regulate Fas
receptor expression, but also produce an increased amount of its soluble form by
modulation of splicing activity such that exclusion of exon 6 is favored. This soluble
version of the receptor is released from the cells and is able to bind to Fas ligand, thus
reducing engagement of membrane-bound Fas and the consequent triggering of Fasmediated apoptosis (Figure 16B, right side).
By monitoring Fas gene expression, we also showed that induction of sFas
synthesis is temporary and occurs only within the first few hours of the response to mild
DNA damage (Figure 15B). This induction coincides with the transient increase of
splicing activity in the p53-deficient cells. Moreover, we have previously shown that
disruption of splicing activity in these cells by siRNA silencing of SRp55 expression
postponed apoptosis, indicating that the observed increase of splicing activity is
functionally important (Filippov et ah, 2007).
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Figure 16. Regulation of Fas expression differs in p53-deficient cells during the early
response to DNA damage. A. A scheme of the p53-dependent response to DNA
damage. p53 induces expression of the Fas gene, leading to an increased amount of Fas
receptor molecules on the cellular surface, thus making the cell more sensitive to FasLmediated apoptosis. B. A scheme of the early response to DNA damage in the absence
of p53. In p53-deficient cells, the total expression of the Fas gene does not change and
activation of AS leads to increased expression of the soluble isoform of the receptor.
This results in a decreased amount of Fas receptor on the cellular surface, accompanied
by the appearance of the soluble anti-apoptotic isoform in the intercellular space, and
resulting in protection of the cell from FasL-mediated apoptosis.
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Identification of the CD44 and Fas genes, coding for receptor molecules with
known functions, as targets for AS following DNA damage sheds light on how activation
of splicing activity may change the cellular response to DNA damage.

The

glycoproteinreceptor, CD44, known to be involved in cell-cell interactions, and its
numerous functionally distinct isoforms are closely connected with apoptosis and
tumorigenesis (Marhaba and Zoller, 2004). The Fas receptor, a powerful inducer of
apoptosis, also exists as a soluble splice variant. Increased expression of its soluble,
anti-apopotic splice isoform, in cells lacking a proper p53 response to DNA damage
indicates that these cells are able to engage a protective mechanism by modification of
splicing activity. This observation may represent one of the mechanisms by which p53
deficient cells become resistant to apoptosis. Further analysis of genes targeted by AS
activity is needed to determine the full extent of how alterations of splicing activity can
modulate cellular responses.

Acknowledgements
This work was supported by NCI Grant R01 CA095461 from the National
Institutes of Health. We would also like to thank Richard Einstein and Weiyin Zhou
(ExonHit Therapeutics) for their suggestions and comments.

87

References
Blanchette, M., Green, R.E., Brenner, S.E. and Rio, D.C., 2005. Global analysis of
positive and negative pre-mRNA splicing regulators in Drosophila. Genes Dev.
19,1306-1314.
Cheng, J., Zhou, T., Liu, C., Shapiro, J.P., Bruaer, M.J., Kiefer, M.C., Barr, P.J. and
Mountz, J.D., 1994. Protection from Fas-mediated apoptosis by a soluble form of
the Fas molecule. Science 263, 1759-1762.
Filippov, V., Filippova, M. and Duerksen-Hughes, P.J., 2007. The early response to DNA
damage can lead to activation of alternative splicing activity resulting in CD44
splice pattern changes. Cancer Res. 67, 7621-7630.
Filippova, M., Brown-Bryan, T.A., Casiano, C.A. and Duerksen-Hughes, P.J., 2005. The
human papillomavirus 16 E6 protein can render cells either sensitive or resistant
to TNF: Effect of dose. Cell Death Differ. 12, 1622-1635.
Filippova, M. and Duerksen-Hughes, P.J., 2003. Inorganic and dimethylated arsenic
species induce cellular p53. Chem. Res. Toxicol. 16, 423-431.
Filippova, M., Parkhurst, L. and Duerksen-Hughes, P.J., 2004. The human
papillomavirus 16 E6 protein binds to Fas-associated death domain and protects
cells from Fas-triggered apoptosis. J. Biol. Chem. 279, 25729-25744.
Filippova, M., Song, H., Connolly, J.L., Dermody, T.S. and Duerksen-Hughes, P.J.,
2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor
(TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277,
21730-21739.
Friesen, C., Herr, I., Krammer, P.H. and Debatin, K.M., 1996. Involvement of the CD95
(APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.
Nat. Med. 2, 574-577.
Gotoh, I., Adachi, M. and Nishida, E., 2001. Identification and characterization of a novel
MAP kinase kinase kinase, MLTK. J. Biol. Chem. 276, 4276-4286.
Gupta, P., Su, Z.Z., Lebedeva, I.V., Sarkar, D., Sauane, M., Emdad, L., Bachelor, M.A.,
Grant, S., Curiel, D.T., Dent, P. and Fisher, P.B., 2006. mda-7/IL-24:
multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol. Ther.
111,596-628.
Heinzen, E.L., Yoon, W., Weale, M.E., Sen, A., Wood, N.W., Burke, J.R., WelshBohmer, K.A., Hulette, C.M., Sisodiya, S.M. and Goldstein, D.B., 2007.
Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's
disease. Genome Biol. 8, R32.

88

Hoffman, B.E. and Lis, J.T., 2000. Pre-mRNA splicing by the essential Drosophila
protein B52: tissue and target specificity. Mol. Cell Biol. 20, 181-186.
Johnson, J.M., Castle, J., Garrett-Engele, P., Kan, Z., Loerch, P.M., Armour, C.D.,
Santos, R., Schadt, E.E., Stoughton, R. and Shoemaker, D.D., 2003. Genome
wide survey of human alternative pre-mRNA splicing with exon junction
microarrays. Science 302, 2141-2144.
Krammer, P.H., 2000. CD95's deadly mission in the immune system. Nature 407 789795.
Marhaba, R. and Zoller, M., 2004. CD44 in cancer progression: adhesion, migration and
growth regulation. J. Mol. Histol. 35, 211-231.
Matlin, A.J., Clark, F. and Smith, C.W., 2005. Understanding alternative splicing:
towards a cellular code. Nat. Rev. Mol. Cell Biol. 6, 386-398.
Novoyatleva, T., Tang, Y., Rafalska, I. and Stamm, S., 2006. Pre-mRNA missplicing as a
cause of human disease. Prog. Mol. Subcell. Biol. 44, 27-46.
Sharma, K., Wang, R.X., Zhang, L.Y., Yin, D.L., Luo, X.Y., Solomon, J.C., Jiang, R.F.,
Markos, K., Davidson, W., Scott, D.W. and Shi, Y.F., 2000. Death the Fas way:
regulation and pathophysiology of CD95 and its ligand. Pharmacol. Ther. 88,
333-347.
Skotheim, R.I. and Nees, M., 2007. Alternative splicing in cancer: noise, functional, or
systematic? Int. J. Biochem. Cell Biol. 39, 1432-1449.
Stamm, S., 2002. Signals and their transduction pathways regulating alternative splicing:
a new dimension of the human genome. Hum. Mol. Genet. 11, 2409-2416.
Thorburn, A., 2004. Death receptor-induced cell killing. Cell Signal. 16, 139-144.
Wettenhall, J.M. and Smyth, G.K., 2004. limmaGUI: a graphical user interface for linear
modeling of microarray data. Bioinformatics 20, 3705-3706.

89

CHAPTER FOUR
CHARACTERIZATION OF FIVE NOVEL SPLICE VARIANTS OF THE TUMOR
SUPPRESSOR IL-24
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Abstract
Interleukin-24 (IL-24) is a cytokine in the IL-10 family that has received a great deal of
attention for its properties as a tumor suppressor and as a potential treatment for cancer.
In this study, we have identified and characterized five novel alternatively spliced
isoforms of this important gene. Several, but not all of these isoforms induce apoptosis in
the osteosarcoma cell line U20S, but none of them affect the survival of the noncancerous NOK cell line. Additionally, the ratio of isoform expression can be modified
by splice factor SRp55. This regulation suggests that alternative splicing of IL-24 is
under tight control in the cell, and can be modified under different cellular conditions
such as DNA damage. Not only do these findings provide new insight into the function of
an important tumor suppressor gene, but they may provide new avenues for cancer
treatment.

Keywords: IL-24, alternative splicing, SRp55, apoptosis
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Introduction
Many diseases, including cancer, are increasingly associated with or caused by
aberrations in alternative splicing (Wang et al., 2003; Venables, 2004; Skotheim and
Nees, 2007; Brinkman, 2004). Alternative mRNA splicing is emerging as a critical player
in the regulation of gene expression and as a method for expanding the proteome
(Johnson et ah, 2003). Splicing is carried out by a complex of proteins and
ribonucleoproteins known as the spliceosome (Black, 2003), and alternative splice site
selection is governed by at least two families of proteins, hnRNPs and the SR family
(Graveley, 2000). Alternative splicing allows much more sophisticated control over gene
expression and cell function than modification of promoter activity alone. It can produce
mRNAs with different stability, alter the function of the protein product by splicing out
regions coding for a particular domain, change enzymatic activity or kinetics, alter
intracellular localization, or introduce stop codons leading to a truncated protein product
(Stamm et al., 2005). Additionally, there are many cases now described where protein
isoforms produced by alternatively spliced transcripts modify the activity of the primary
isoform by heterodimerizing, blocking receptor sites, or other means (Stamm, 2002). In
this study we investigate the splicing of the tumor suppressor Interleukin-24.
Interleukin-24 (IL-24) is a cytokine in the IL-10 family (Caudell et al., 2002). The
receptors for IL-24 are associated with the JAK/STAT pathway, which affects
transcriptional regulation, particularly of genes involved in cell differentiation,
proliferation and apoptosis. IL-24 was originally described as melanoma differentiationassociated gene 7 (mda-7) in studies identifying transcripts that were differentially
expressed in melanoma cells induced to terminally differentiate (Jiang et al., 1995). IL-
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24 was found to be constitutively expressed in normal melanocytes, and the expression
level decreases progressively in benign nevi, in situ melanoma, invasive melanoma and
metastatic melanoma (Ellerhorst et ah, 2002). IL-24 is able to induce apoptosis by both
the intrinsic and extrinsic apoptotic pathways, independently of other common tumor
suppressor genes such as p53, pRB, and p21 (Lebedeva et ah, 2003; Lebedeva et ah,
2005; Su et ah, 2003). These findings supported the putative role of IL-24 as a tumorsuppressor. Over-expression of IL-24 was found to suspend growth and induce apoptosis
in many different tumor cell types, including those representing melanoma, breast cancer,
pancreatic cancer, prostate cancer, lung cancer, malignant gliomas, hepatomas, renal
carcinoma, ovarian cancer, and others, while having no apparent effect on normal cells
and cell lines (Chen et ah, 2005; Leath et ah, 2004; Lebedeva et ah, 2002; Lebedeva et
ah, 2003; Saeki et ah, 2000; Su et ah, 1998; Su et ah, 2003; Yacoub et ah, 2003).
Additionally, injection of the construct into solid tumors caused a reduction in the size of
tumors, enhanced the lethal effects of radiation on tumor cells, and displayed potent
antitumor bystander activity. Phase I/II clinical trials are currently underway in humans
(Cunningham et ah, 2005; Tong et ah, 2005).
IL-24 has emerged as an important tumor suppressor gene because of its unique
ability to induce apoptosis in a wide variety of cancer cells while having no apparent
effect on normal cells. Because of these characteristics, research has progressed quickly
into the stage of clinical trials. However, while its efficacy as a cancer treatment is
promising, there is still some controversy regarding the mechanism of action of IL-24,
with some groups contesting its ability to induce apoptosis in cancer cells as recently as
2007 (Kreis et ah, 2007).
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Most evidence supports the ability of IL-24 to function intracellularly to induce
apoptosis and inhibit tumor growth. Many of the initial studies into the function of mda7/IL-24 took place prior to its classification as an interleukin, and utilized an adenoviral
vector delivery system (Ad-mda7), thus expressing the protein intracellularly. IL-24 was
found to activate multiple apoptosis signaling molecules, some of which appeared to be
cell-type specific. The apoptosis induced by IL-24, which involves the caspase cascade
(Saeki et ah, 2000), occurred independently of p53, Ras, Rb, and p21 (Lebedeva et ah,
2003; Lebedeva et ah, 2005; Mhashilkar et ah, 2001; Su et ah, 2003), and was observed
in a wide variety of tumor cell types. The cytokine functions of IL-24 are mediated
through IL-20R1/IL20R2 and IL-22-R1/IL-20R2 receptors. The classification of IL-24 as
a cytokine triggered interest in its receptor-mediated activity, including speculation that
secretion and receptor-mediated activity may be responsible for the anti-tumor
“bystander” activity observed in cells not directly infected with the IL-24 expressing
virus Ad-mda-7 (Chada et ah, 2004; Lebedeva et ah, 2007; Su et ah, 2005). The
receptors for IL-24 are associated with the JAK/STAT pathway, which affects
transcriptional regulation, particularly of genes involved in cell differentiation,
proliferation and apoptosis (Gopalkrishnan et ah, 2004; Sauane et ah, 2004). IL-24 is
indeed glycosylated and secreted (Lebedeva et ah, 2005; Mhashilkar et ah, 2001), and is
secreted even from cells infected with Ad-mda-7 (Chada et ah, 2004; Sauane et ah,
2004). However, while the exogenous protein is cytotoxic to tumor cells, the mechanisms
are unclear. Binding to its receptors, IL-24 activates STAT3, and to a lesser extent
STAT1 (Parrish-Novak et ah, 2002), but this activation isn’t essential for tumor cell
killing (Chada et ah, 2005; Zheng et ah, 2007). Further, the purified protein exerts its
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cytotoxic activity regardless of the receptor status of the tumor cells (Lebedeva et ah,
2005).

Anti-tumor effects can be exerted through the immune system, in addition to effects
triggering apoptotic pathways. Investigation into the immune function of IL-24 found that
unlike IL-10, which exhibits primarily immunosuppressive Th2-type activity, IL-24 is
immunostimulatory. When applied to PBMCs in culture, IL-24 induced activation and
production of TNF-a, IL-1, IFN-y, IL-6 and GM-CSF (Caudell et ah, 2002). This
immunostimulatory function was confirmed in the clinical trial, which observed an
increase in these cytokines in the serum of patients who had received an intratumoral
injection of Ad-Mda-7 (Tong et al., 2005).
Interleukin-24 consists of 7 exons and 6 introns (Huang et al., 2001) (Figure 17,
Upper Panel), with three different splice variants reported in the literature, two of which
have been validated and deposited in the Ref Seq database. Allen et al describe a splice
variant lacking exons 3 and 5, termed mda-7s (Allen et al., 2004). They predicted that
mda-7s heterodimerizes with full-length IL-24, but found no effect of mda-7s on the
kinetics of cell death induced by full-length IL-24. Expression analysis found mda-7s in
normal melanocytes but reduced or absent expression in melanomas, leading the
researchers to speculate that loss of this splice variant is associated with tumor
progression. A second report by the same group identified splice variants of IL-24
lacking either exon 3 or exon 5, but no functional analysis of these variants was
conducted, and they have not been validated by other studies (Allen et al., 2005). A
recent study of the mouse analog for IL-24 (FISP) found a novel splice variant that lacks
29 nucleotides from the 5’ end of exon 4 (Sahoo et al., 2008). These results indicate that
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Figure 17. The exon structure of IL-24: Upper Panel: IL-24 consists of 7 exons, all of which are utilized in the expression
of the full-length isoform. Key features of the gene include the initial methionine on exon 2, the signal peptide cleavage
site on exon 3, and the IL-10 family signature sequence on exon 5. Expression terminates near the beginning of exon 7.
Lower Panel RT-PCR using primers designed to amplify the region between exons 1 and 7 demonstrates that there are
numerous distinguishable isoforms of differing lengths.
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the variant (FISP-sp) dimerizes with the full-length version, blocks its secretion, and
inhibits the induction of apoptosis. Alternative splicing is commonly reported for other
human interleukin genes as well, including IL-2, IL-4, IL6, IL-7, IL-10 and IL-21 (Alms
et ah, 1996; Bihl et ah, 2002; Korte et ah, 1999; Rahman et ah, 2007; Tsytsikov et ah,
1996; Wu et ah, 2005). In many of these cases, the alternative protein isoform functions
to modulate the activity of the primary interleukin.
We previously observed that RT-PCR amplification of IL-24 yields at least 4
distinguishable transcriptional isoforms (Filippov et ah, 2008). That observation
prompted us to investigate further. In this study we set out to characterize these isoforms
and have now described five novel splice variants of IL-24 in addition to the two
isoforms currently deposited in the RefSeq database. These isoforms have varying effects
on the viability of U20S cells (derived from an osteosarcoma). Our results suggest that
there may be the potential for increased efficacy of IL-24 in the treatment of human
cancers.

Materials and Methods
Cell Lines and Cell Culture
U20S cells, derived from a human osteosarcoma, were obtained from the ATCC.
HCT116 cells were a kind gift from Dr. Bert Vogelstein (Bunz et ah, 1998). These two
cell lines were cultured in McCoy’s 5A medium (Invitrogen) supplemented with 10%
fetal bovine Serum (PAA Laboratories), penicillin (100 U/ml) and streptomycin (100
pg/ml) (Sigma-Aldrich). DU145 cells were obtained from the ATCC and cultured in
MEM (Invitrogen) supplemented with 10% fetal bovine Serum (PAA Laboratories),
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penicillin (100 U/ml) and streptomycin (100 pg/ml) (Sigma-Aldrich). NOK cells, a
normal oral keratinocyte cell line immortalized by hTERT, were a kind gift from Dr. Karl
Munger (Piboonniyom et al., 2003). NOK cells were cultured in KSFM medium
(Invitrogen).

Cloning and Sequence Analysis of IL-24 Splice Variants
Total RNA was isolated from U20S, HCT116, and DU 145 cells using TRIzol
Reagent (Invitrogen) and used as a template to produce cDNA using Superscript III
Reverse Transcriptase (Invitrogen) according to the manufacturer’s instructions. Primers
were designed complementary to exons 1 and 7 of IL24 to encompass the entire ORF of
any splice isoform containing the first and last exons:
GAAGATCTGA ATTTTC AAC AGAGGCTGC AA and
GCTCTAGAGAGCTT GTAG AATTTCT GCA (includes an added Xbal restriction site).
RT-PCR was performed at 94°C for 30 sec, at 57°C for 30 sec, and 72°C for 1 minute for
35 cycles using Taq DNA Polymerase (NEB, Beverly MA). Total PCR product was
cloned into the pCR Blunt-TOPO vector (Invitrogen) according to the manufacturer’s
instructions. Plasmids from the TOPO cloning reaction were transformed into competent
E. coli, plated on selective medium and grown into colonies. Individual colonies were
screened by RT-PCR using the primers described above. Colonies containing different
sized fragments were amplified in selective medium, DNA was isolated using the Zyppy
Plasmid Miniprep Kit (Zymo Research) and sequenced.
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Subcloning
Constructs were subcloned from the pTOPO vector into the pFLAG-Myc-CMV22 vector (Sigma-Aldrich). Sequences correctly oriented in TOPO were cloned by cutting
at the Sad and Xbal sites and cloned into the same cut sites on pFLAG-Myc-CMV-22
(removing the FLAG tag but maintaining the Myc tag). Sequences that were reversed in
TOPO were cloned by cutting at the Xbal and EcoRV (blunt) sites and cloned into the
Xbal and Fell3611 (blunt) sites on pFLAG-Myc-CMV-22. For sublconing into the
retroviral pLNCX vector (Clontech), the gene sequence together with the Myc tag were
amplified by RT-PCR (primer sequences: ATGGGCGGTAGGCGTGTAC and
GCTCTAGAGAGCTTGTAGAATTTCTGCA) and blunt cloned into the pLNCX vector,
which was digested with Hpal and dephosphorylated with alkaline phosphatase (Roche).

Transfections
Transfections were carried out using TransIT-LTl Reagent (Mims Bio) according
to the manufacturer’s instructions.

Immunoblotting
Cells (4 x 105 to 1 x 106) were lysed in 50 to 100 pi Laemmli buffer for 10
minutes on ice. Lysates were subjected to 8% or 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon FL
membranes (Millipore, Billerica MA). Anti-c-myc Clone 4AB monoclonal antibodies
(Sigma), were applied at a 1:1000 dilution. HRP-conjugated secondary anti-mouse
antibodies (Pierce) or fluorescently tagged secondary anti-mouse antibodies (Li-Cor
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Biosciences) (1:5000 and 1:15000 dilution, respectively) were used for detection. HRP
conjugated secondary antibodies were detected using the chemiluminescent SuperSignal
West Pico or Femto Maximum Sensitivity substrate (Pierce). Fluorescent antibodies were
detected using the Odyssey Infrared Imaging system (Li-Cor Biosciences).

Cell Viability Assays
MTT Assay: Cells were plated in 96 well tissue culture plates (5 x 104 cells per
well), transfected as described above, and at the indicated incubation times, cell viability
was measured. 20 pi of MTT was added (5 mg/ml stock) to the medium in each well and
cells were incubated at 37°C for 2 hours. The medium was removed and 150 pi of
Me2SO was added to each well, mixed by pipetting, and the absorbance of each well was
measured at 490 mn. Cell Titer-Glo Assay (Promega): This assay was used instead of
MTT for NOK cells; the two assays were first compared for the same transfection, and
the data correlated. Cells were grown in 96 well tissue culture plates. At the noted time
points after transfection, the Cell Titer-Glo reagent was added to the cell culture medium
and mixed on a rotating shaker. After 10 minutes incubating at room temperature, light
emission was read using a luminometer.

Colony Forming Assays
Cells were plated in 6 well tissue culture plates, and transiently transfected as
described above with one of the various IL24 isoforms. Parallel plates were co
transfected with GFP to normalize for transfection efficiency. After 48 hours, cells were
trypsinized. GFP co-transfected cells were lysed and GFP intensity was measured using a
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fluorescent plate reader. The remaining cells were resuspended in 1 ml of medium, re
seeded to different densities (500 pi, 100 pi and 20 pi per well) and then passaged in
selective medium containing G418 (500 pg/ml). Following 2 weeks of selection, colonies
were fixed with formalin, stained with crystal violet, and the colonies were counted.

Caspase 3/7 Activity Assay
Cells were plated in 24 well tissue culture plates and transiently transfected with
the vector control, or the IL-24 constructs. After 24 hours, cells were lysed in 100 pi
Passive Lysis Buffer (Promega). 50 pi was used to normalize for cell number using the
Cytotox-Glo assay (Promega) according to the manufacturer’s instructions. The rest of
the lysate was subjected to a fluorescence based Caspase 3/7-Glo Assay (Promega)
according to the manufacturer’s instructions.

Results
Expression of IL-24 Splice Isoforms in U20S Cells
While IL-24 has only 2 isoforms currently deposited in the RefSeq database, we
previously observed that RT-PCR amplification of IL-24 in U20S cells using a primer
set that spans the entire transcript yields at least 4 distinguishable splice isoforms
(Filippov et ah, 2008). The mRNA expression of these splice variants in U20S cells is
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Figure 18. Expression of IL-24 isoforms is influenced by splice factor SRp55: U20S
cells were transiently transfected with a plasmid expressing SFRS6, the gene that codes
for splice factor SRp55. Total mRNA was isolated using Trizol (Invitrogen), cDNA was
reverse-transcribed (ImProm II, Promega) Upper panel: IL-24 primers. Over-expression
of SFRS6 results in a shift in isoform ratio away from the larger isoforms and towards the
smaller isoforms. Lower panel: primers directed against cofilin for control.
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shown in Figure 17, Lower Panel. Since our initial analysis determined that one of the
isoforms was upregulated by the silencing of splice factor SRp55, we further investigated
the regulation of IL-24 splicing by over-expressing this splice factor. U20S cells were
transiently transfected with a plasmid expressing the SFRS6 gene which codes for splice
factor SRp55, or with a vector control. After 48 hours, total RNA was isolated from the
cells, and RT-PCR was performed. We found that over-expression of SFRS6 causes a
dramatic shift in IL-24 splicing away from the larger iso forms, and in particular, an
increase in the smallest isoform (Figure 18). This data suggests that the distribution of
these splice isoforms is responsive to events that influence the activity of one or more
splice factors.

Characterization of Seven Alternatively Spliced Isoforms of IL-24
We set about to characterize these additional transcripts by cloning RT-PCR
products from U20S, (Figure 17, Lower Panel) HCT116, and DU175 cells (not shown)
into the pCR-Blunt-TOPO vector and sequencing the resulting plasmids. Our analysis
revealed 6 differentially spliced transcripts from the IL-24 gene (Figure 19) in addition to
the full-length transcript. The full-length transcript contains all 7 exons. Isoform 2, as
previously described (mda-7S, or IL-2453,5) lacks exons 3 and 5, although we did not
isolate this isoform from the tumor cell types we analyzed. In addition, we characterized
several transcripts lacking exons 2, 3, and 5 in various combinations. In all cases, exons
were spliced in or out in their entirety. Transcripts were sequenced that lack exon 5 (IL2455), exons 2 and 3 (IL-2452,3), exons 2 and 5 (IL-2452,5), exons 2, 3 and 5 (IL2452,3,5) and exon 2 (IL-2452) (Figure 19). The open reading frame of the full-length
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Figure 19. Characterization of IL-24 splice variants: Schematic representation of the exon
structure of IL-24 splice variants. The exons that are spliced out in the various forms
include exon 2 which contains the initial methionine, exon 3 which contains the signal
peptide cleavage site, and exon 5 which contains the IL-10 signature sequence. The five
novel isoforms are highlighted by the red box.

107

IL-24FL

EL-2463j
(mdaTil

108

Figure 20. Characterization of IL-24 splice variants: Clustal alignment of the predicted
amino acid sequences generated by the open reading frame of the different splice
isoforms. A single asterisk (*) indicates those isoforms for which we have observed
protein products. Two asterisks (**) indicate Isoform 2, which we have been unable to
isolate in any of the cell lines we analyzed, indicating that expression of the isoforms may
vary between tumor cell types.
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IL-24 generates a protein with 206 amino acids (aa). The open reading frame of mda-7s
generates a 63 aa protein. Predicted open reading frames for the novel isoforms we have
identified are shown in a Clustal alignment in Figure 20. The predicted open reading
frame for IL-2455 spans exons 2 through 7. The open reading frame for IL-2452,3 is
predicted to span exon 6 and terminate on exon 7. The open reading frame for IL-2482,5
encompasses sequences from exons 3, 4, 6, and 7. The open reading frame for IL-2452
includes sequences from exons 3 through 7. The open reading frame for IL-2452,3,5 is
predicted to include sequences from exons 6 and 7.

mRNA and Protein Expression of the Splice Isoforms of IL-24
The full-length IL-24 isoform and the five novel isoforms described were
subcloned from the pCR-Blunt-TOPO vector into the pFLAG-Myc-CMV-22 vector for
expression in mammalian cells. Expression for all 5 novel isoforms was verified at the
mRNA level (Figure 21). Plasmids were transfected into U20S cells, and after 48 hours,
mRNA was isolated and used to generate cDNA. IL-24 was amplified by RT-PCR and
run in an agarose gel containing ethidium bromide. The isoforms are visualized under
UV: IL-2455 at 502 bp, IL-2452,3,5 at 160 bp, IL-2452,3 at 219 bp, IL-2452,5 at 324 bp,
IL-2452 at 518 bp. In order to visualize the isoforms at the protein level, the isoforms
were cloned in sequence with the c-terminal myc tag on the pFLAG-Myc-CMV-22
vector. Plasmids were transfected into U20S cells, which were lysed 48 hours later. The
lysates were separated by SDS-PAGE, transferred to a PVDF membrane and probed with
antibodies to the c-myc terminal tag. With immunoblotting, the full-length IL-24 protein,
as well as IL-2452,5 and IL-2452 were observable (Figure 21). We were unable to detect
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Figure 21. Expression of IL-24 splice variants: (A) Expression of IL-24 constructs after
transient transfection into U20S cells. Total mRNA was isolated using Trizol
(Invitrogen), and cDNA was reverse-transcribed (ImProm II, Promega) Upper panel: IL24 primers. Lower panel: primers directed against cofilin for control. (B) Expression of
11-24 constructs after transient transfection into U20S cells. Total cell lysates were
collected using Laemli lysis buffer, sonicated, separated by SDS-PAGE, transferred to
PVDF membrane and probed using anti-c-myc antibodies. IL-2455, IL-2482,3,5, and IL2482,3 were not detectable by traditional Western Blotting, although they do produce an
effect when transfected into cells.
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IL-2455, IL-2462,3,5, or IL-2482,3 by immunoblot. Immunoprecipitation using
polyclonal anti-c-myc anbibodies and Protein G-Agarose beads for IP and monoclonal cmyc antibodies for detection was also unable to detect these three isoforms at the protein
level. It is possible that these transcripts are not translated into protein products.

Full Length IL-24, IL-2452,3,5, IL-2452,3 and IL-2452,5
Reduce Cell Viability in U20S Cells
IL-24 has attracted research attention for its ability to selectively induce apoptosis
in cancer cells while having relatively little effect on normal cells. We therefore wanted
to determine what, if any, function the novel splice isoforms of IL-24 might possess. To
evaluate the effects of the isoforms on survival of a cancer cell line, a colony forming
assay was performed. The individual isoforms were transiently transfected into U20S
cells. Parallel plates of cells were co-transfected with GFP to normalize for transfection
efficiency. After 48 hours, GFP was measured; the rest of the cells were resuspended and
split to multiple densities. Once they had attached, they were placed under neomycin
selection for 2 weeks. The cells were fixed with formalin, stained with crystal violet and
the colonies were counted. Representative plates are shown (Figure 22, Upper Panel)
along with a graph of colony numbers normalized by GFP for transfection efficiency
(Figure 22, Lower Panel). To determine how quickly this change in viability could be
detected, U20S cells were seeded in 96 well plates and transiently transfected with the
various isoforms. An MTT assay was performed at 48, 72, and 96 hours post
transfection. Compared to the vector control, significantly reduced viability was observed
in cells transfected with the full-length isoform, and an even greater reduction in cells
transfected with IL-2452,3,5 (Figure 23, Upper Panel).
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Figure 22. Effect of IL-24 splice variants on cell viability: Upper Panel: Colony forming
assay demonstrates the ability of the IL-24 isoforms to differentially affect cell viability.
Lower Panel. Colony count normalized by GFP transfection efficiency.
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Figure 23. Effect of IL-24 splice variants on cell viability: Upper Panel. MTT survival
assay after transient transfection of the isoforms into U20S cells demonstrates that the
same trend seen in the colony forming assay can be seen as early as 72 hours after
transfection, and is even more pronounced at 96 hours. Lower Panel: Survival assay after
transient transfection of the isoforms in non-cancerous NOK cells demonstrates that the
isoforms do not affect survival in this non-cancer cell model, indicates significantly
lower viability than the vector control at the same time point (p < 0.05).
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The IL-24 isoforms have no effect on cell viability of NOK cells
One of the major features of IL-24 that makes it suitable for cancer therapy is its
specificity in inducing apoptosis only in tumor cells, while having no appreciable effect
on normal cells. In order to evaluate the cancer-specific effects of our novel splice
isoforms, we utilized NOK cells, a non-cancerous immortalized cell line derived from
normal oral keratinocytes (Piboonniyom et ah, 2003). Cells were seeded in 96 well
plates and transiently transfected with the splice isoforms. A luminescent-based cell
viability assay was performed at 48, 72, and 96 hours post-transfection. None of our IL24 isoforms had any effect, indicating that the isoforms share the cancer-specificity of
full length IL-24 (Figure 23, Lower Panel).

Full Length IL-24, and its Isoforms Activate Caspases,
with the Exception of IL-2482
The previously described experiments measured cell viability, but did not
determine whether the reduced viability we observed was due to a halting of
proliferation, apoptosis, or another form of cell death. Full-length IL-24 has a welldemonstrated ability to induce apoptosis in many cancer cell types. To determine if the
observed decrease in viability was the result of apoptosis, a caspase 3/7 assay was
performed. 24 hours after transfection, cells were lysed and the lysates were divided to
assess caspase 3/7 activity and normalized for cell number. The results of these assays
demonstrate that full-length IL-24 and its isoforms, with the exception of IL-2482,
induced activation of caspases 3 and 7 more than 2-fold when compared to the vector
control (Figure 24).
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Figure 24. Mechanism of cell death: U20S cells were transiently transfected with the
splice isoforms of IL-24, or a vector control and allowed to grow in culture for 24 hours.
Cells were lysed with a passive lysis buffer and the lysates were subjected to a luciferasebased caspace 3/7 activity assay (Promega). Results shown are normalized for cell
number. Both IL-24 full length and several of the isoforms (although not 52) show more
than a two-fold induction of caspase 3 and 7 activity when compared to the vector
control, indicating that the isoforms of IL-24 are inducing a caspase-dependent apoptotic
pathway. * Indicates significantly higher caspase 3/7 activity than the vector control (p <
0.05). ’
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Discussion
In this study, we have identified and characterized five novel mRNA splice isoforms of
IL-24, defining their mRNA and predicted protein structures, as well as their effects on
cell viability. The wide variety of effects observed for this single gene makes our
observation of multiple distinct transcripts of the IL-24 particularly interesting. Our initial
observation of multiple, previously unknown splice variants of IL-24 (Filippov et al.,
2008) was intriguing, and led us to investigate their makeup. In the tumor cell lines we
analyzed (U20S, DU175, and HCT116), we identified 5 novel splice variants not
previously recognized. Isoforms previously deposited in RefSeq are the full length IL-24
(Isoform 1) which contains all 7 exons, and a shorter isoform lacking exons 3 and 5
(Isoform 2, or mda7-S) (Allen et al., 2004). We were unable to isolate Isoform 2 from
any of the tumor cell lines we analyzed. However, we characterized 5 novel isoforms
lacking various combinations of exons 2, 3, and 5. Although one report (Allen et al.,
2005) describes isoforms lacking either exon 3 or exon 5, no follow-up to this study
provided any confirmation and neither was deposited in the RefSeq database.
Additionally, while we have described isoform IL-2485, we were unable to isolate the
second isoform described by Allen et al, IL-2483. The different sets of isoforms detected
by ourselves and others suggests that the expression and distribution of IL-24 isoforms
may be cell-type specific.
Initially, we predicted potential protein products for the 5 novel isoforms, and
attempted to confirm their expression in mammalian cells. While we were able to
consistently express the 5 novel isoforms at the mRNA level, we were only able to
visualize two of them (IL-2482 and IL-2482,5) at the protein level. This was not entirely
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unexpected, as genes often create nonsense splice isoforms, or mRNA splice variants that
are not expressed at the protein level. However, we continued our analysis with all of the
splice variants, since non-coding RNAs can still have a biological function (Taft et ah,
2010).
The most intriguing aspect of our analysis into the function of the novel IL-24
splice isoforms was the survival data. None of the splice variants had any effect on the
non-cancerous NOK cell line, but several of them, especially IL-2482,3,5, dramatically
reduced viability in the cancer cell line U20S (derived from an osteosarcoma). IL2482,3,5 is one of the splice isoforms we have been unable to identify at the protein level.
However, its effect on cells is clear, as it reproducibly reduces cell viability and activates
caspases 3 and 7. There are several possible reasons for this. The first possibility, that the
c-terminal myc tag that we used for immunoblotting was out of sequence with the protein
product of IL-2482,3,5, was quickly ruled out. Sequence analysis of the three reading
frames of this mRNA product confirmed that our predicted 48 amino acid protein product
was the longest potential product that could be generated, and it is in frame with the cterminal myc tag. The next longest potential peptide product is only 25 amino acids in
length, and it is highly unlikely that it would be preferentially expressed over a protein
more than twice as long. The second possibility is that the protein product is not
detectable by immunoblot, either because its small size is allowing it to pass through the
pores of the membrane, or because the protein is folding in such a way as to make the
myc tag inaccessible to antibodies. We attempted to overcome the potential size issue by
immunoprecipitation utilizing anti-c-myc antibodies and protein A/G agarose beads,
followed by a polyclonal anti-c-myc antibody for detection. Immunoprecipitation is a
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frequently used and well-optimized technique in our laboratory, but we were unable to
detect a protein product of IL-2482,3,5 by this method. The final possibility is that IL2482,3,5 is not expressed as a protein product at all, and is instead acting at the mRNA
level.
An important question arises as to the regulation of these alternative splice
isoforms of IL-24. While splice site selection is a complicated process that has not been
completely elucidated, there is growing understanding of the role of the SR family of
proteins. We initially observed additional splice isoforms of IL-24 in a study examining
the splice factor gene SFRS6, which codes for the SRp55 protein (Filippov et al., 2008).
Silencing of that splice factor was shown to increase the expression of IL-2482,3. In this
study we have demonstrated that over-expression of SFRS6 causes an overall shift in the
splicing of IL-24 away from the larger isoforms, and particularly toward the smallest
isoform, IL-2482,3,5. While the reason for this shift is still unknown, our data from these
studies suggests that IL-24 splice site selection is not random, but is governed at least in
part by the SR family protein SRp55. The non-random nature of IL-24 splice site
selection is also supported by the observation that Isoform 2 (mda7-S) expression
decreases with tumor progression (Allen et al., 2004). Our data supports and extends the
literature and suggests a specific role for IL-24 splicing in the cell’s response to different
conditions, including DNA damage, stress, and potentially cancer.
In summary, we have identified five novel mRNA splice isoforms of the
important tumor suppressor gene IL-24. These isoforms have varying effects on cell
survival in an osteosarcoma tumor cell model. Specifically, several of the isoforms—IL2485, IL-2482,3, and IL-2482,5—activate caspases and induce apoptosis with similar
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efficacy as full length IL-24. One of the isoforms, IL-2452,3,5, demonstrated a consistent
ability to induce apoptosis even more effectively than the full-length IL-24, while having
no effect on a non-cancerous cell line. Finally, one of the isoforms, IL-2452, did not
induce caspase activity or affect cell survival. These results indicate that some of these
isoforms could be at least as efficacious, if not more so, than the full-length IL-24 as a
potential cancer treatment. Additionally, the presence of multiple isoforms with differing
levels of effectiveness could provide some explanation for the multiple pathways
reported to be involved in IL-24-induced, cancer-specific apoptosis.
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CHAPTER FIVE
DISCUSSION

Summary of Findings
Our objective for this study was to describe how a cell can modify its splicing
patterns, with consequential functional changes, in response to external events. In
particular, we have shown that the splice factor SFRS6 is up-regulated in response to
DNA damage, and that the binding of p53 to the promoter abrogates this response by
binding directly to responsive elements on its promoter region. The levels of SFRS6
expression, and of its protein product SRp55, have effects on the splicing of several target
genes. For example, silencing of SFRS6 changes the splice isoform ratios of several
genes related to apoptosis, including Interleukin-24. Over-expression of SFRS6 also
modifies IL-24 splicing. IL-24 has at least 7 distinct splice isoforms, only two of which
have been deposited in the RefSeq database. The other five, which we have described in
this work, are novel. Some, but not all of the IL-24 isoforms induce apoptosis in a cancer
cell line, but do not affect the survival of a non-cancer cell line. Overall, these studies
demonstrate that external events such as DNA damage can work through splice-related
pathways to influence cellular death and survival decisions. These findings have the
potential to impact our understanding of and approach to any human disease in which
cells inappropriately survive or die, including cancer and neurodegenerative diseases.
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p53 and the Response to DNA Damage
Since its discovery, the p53 protein has emerged as central to the cellular response
to stress, and can initiate the reaction to stressors through a number of key pathways
leading to cell-cycle arrest, DNA repair, and apoptosis. Many of its functions are related
to its activity as a transcription factor, a function which is carefully regulated in healthy
cells (Laptenko and Prives, 2006). The predominant negative regulator of p53 is Mdm2,
which both functions as an E3 ubiquitin ligase and blocks transcription of p53 (Brooks
and Gu, 2003). In response to stress, p53 is stabilized by inhibition of Mdm2.
Additionally, other proteins can stabilize p53, and it is modified by both phosphorylation
and acetylation, leading to conformational changes that increase its ability to bind to
DNA (Brooks and Gu, 2003). It then functions as a transcriptional activator for many
genes related to cell cycle arrest (p21 and others), DNA repair (GADD45, Pol(3 and
others), and apoptosis (Bax, Fas, PUMA, NOXA, APAF-1, DR5 and others) (Hofseth et
ah, 2004; Liu and Chen, 2006; Tokino and Nakamura, 2000).
Most of the stress-response functions of p53 described above are achieved
through transcriptional activation. However, while its functions as a transcriptional
activator have been widely published, evidence indicates that it acts as a transcriptional
repressor nearly as frequently (Kannan et ah, 2001) if not more often (Kho et al., 2004).
Thus, the results of our studies demonstrating the mechanism by which p53 blocks the
up-regulation of SFRS6 fit into a growing body of literature examining p53 as a
transcriptional repressor. As a transcriptional activator, p53 functions by binding to
consensus sequences on the promoter, facilitating promoter opening and by recruiting
other transcription factors through direct interactions. p53-mediated transcriptional
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repression appears be achieved through diverse mechanisms, with some studies reporting
direct p53 binding to the promoter (Hoffman et ah, 2002; Johnson et ah, 2001; Yang et
ah, 2008), while others report more complex mechanisms. p53 may interact with
transcription factor Sp-1 and repress transcription via Sp-1 recognition sites on the
promoter (Innocente and Lee, 2005; Wilson et ah, 2009). Promoter methylation initiated
by p53 binding to DNMT-1 can also lead to transcriptional repression (Esteve et ah,
2005). p53 can also target G2/M promoters for repression via interaction with NF-Y.
Both the intrinsic and extrinsic apoptotic pathways can involve p53 (Haupt et ah,
2003), but this protein is mutated or inactive in half of human cancers. Such p53 null or
mutant cancer cells can frequently be induced to undergo apoptosis, however
(Abeysinghe et ah, 2001; MacFarlane et ah, 1996; Peled et ah, 1996), and they do it
through alternative apoptotic pathways, such as the pathway mediated by ceramide
(Bose et ah, 1995; Perry et ah, 2000; Strum et ah, 1994; Tepper et ah, 1999). How the
cellular machinery activates these alternative pathways only in the absence of p53 is still
not clearly understood. The model pathway described in this research defines one way
that this can be achieved. Normal levels of p53 in the cell not only carry out the p53dependent response to stress, but they also repress an alternate stress-response pathway.
Our lab previously reported that in the absence of p53, SFRS6 expression is up-regulated
in response to DNA damage (Filippov et ah, 2007). The studies described in this report
confirm that this inhibition is achieved by direct p53 binding to the SFRS6 promoter.
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Transcriptional Regulation of Splice Factors
Three major mechanisms are currently described that modify splice factors and
thereby alter splice site selection. Splice factors can be regulated by changing their
expression level, changing their phosphorylation status or by changing their localization
within the cell. The SR proteins in particular are modified by extensive phosphorylation
of the serine residues in the RS domain, which affects their localization and function
(Graveley, 2000). Less is known, however, about the direct transcriptional regulation of
the SR proteins themselves. It has been extensively demonstrated that the expression of
these proteins is tissue specific and concentration dependent (Chiu and Ouyang, 2006;
Grosso et al., 2008; Pettigrew and Brown, 2008), but the mechanism for their regulation
is not well-described, and there are few cases describing their transcriptional regulation in
response to different cellular conditions. One group demonstrated that SC35 is upregulated by E2F1, contributing to the induction of apoptosis (Merdzhanova et al.,
2008). Other reports have also demonstrated the importance of SR protein expression in
apoptotic progression (Blaustein et al., 2005; Li et al., 2005). Additionally, SR protein
expression is extensively modified in cancer (Skotheim and Nees, 2007) and other
diseases including HIV (Dowling 2008). Our research showing the up-regulation of
SFRS6 in response to DNA damage, and the inhibition of this up-regulation by p53,both
previously (Filippov et al., 2007; Filippov et al., 2008) and reported herein contributes to
this growing understanding of splicing regulation.
A cell’s response to DNA damage is critical for prevention of tumorgenesis.
Following DNA damage, two PI3-kinase related protein kinases, ATM and ATR, are
activated. They phosphorylate proteins involved in DNA repair, cell cycle progression
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and apoptosis, such as E2F1, p53, and Cdc25 (Gasser et aL, 2005). As described above,
p53 is a critical component in the cell’s DNA damage response. Our research
demonstrates that in addition to these important functions, it acts as a dominant inhibitor
of an alternative DNA damage response pathway involving splice factor SFRS6. In
situations where p53 is mutated or non-functional, this alternate pathway is activated.
Future research should investigate the mechanism by which SFRS6 transcription is upregulated in response to DNA damage. Potential candidates include other components of
the ATM/ATR response pathway, such as E2F1. E2F1 has been demonstrated to activate
splice factor SC35 (Merdzhanova et ah, 2008), contributing to the induction of
apoptosis. Other potential activators of SFRS6 may be outside the ATM/ATR pathway.
One such candidate is NF-kappaB, which is activated in response to a wide variety of cell
surface receptors, and regulates genes related to cell cycle and apoptosis (Gilmore,
2006). Understanding both the activation and inhibition of SFRS6 will further contribute
to our knowledge of regulated alternative splicing as a cellular response to stress.

Splicing of Interleukin 24
Our investigation into the regulation of SFRS6 and its target genes revealed that
IL-24 has much more complicated splicing than has previously been reported. We have
now described five novel splice variants of this important tumor suppressor. While we do
not yet entirely understand the regulation of this splicing, it is at least partially under the
control of SRp55. The function of all of these isoforms in various tissue types and under
various cellular conditions remains to be elucidated. However, we have now
demonstrated that some, but not all of these isoforms induce apoptosis in a tumor cell
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line, and have no effect on survival in a non-cancerous cell line. Exactly how the
different isoforms interact in the cell is not known. It is possible that the isoforms interact
to modify the function of the full-length IL-24. Many interleukins, including IL-2
(Denesyuk et al., 1998; Tsytsikov et ah, 1996), IL-4 (Alms et ah, 1996; Arinobu et ah,
1999; Atamas et ah, 1996; Zav'yalov et ah, 1997), IL-6 (Bihl et ah, 2002; Denessiouk et
ah, 2008), IL-7 (Goodwin et ah, 1989; Korte et ah, 1999), IL-10 (Wu et ah, 2005), IL15 (Barzegar et ah, 1998; Nishimura et ah, 2005), and IL-21 (Rahman et ah, 2007) have
been reported to have distinct splice variants, some of which function by interacting with
the full-length version of that interleukin to modify its function (Arinobu et ah, 1999;
Atamas et ah, 1996; Denessiouk et ah, 2008; Denesyuk et ah, 1998; Nishimura et ah,
2005; Sahoo et ah, 2008; Zav'yalov et ah, 1997).
Future study of the splice variants of IL-24 should investigate the tissue
specificity of their expression and possible functional interactions between the isoforms.
It may be particularly relevant to focus future research on IL-2482,3,5, which we have
demonstrated to induce apoptosis in an osteosarcoma cell line even more strongly than
the full length IL-24. IL-24 itself is already showing great promise as a cancer treatment,
both alone and in combination with radiation or chemotherapy (Sarkar et ah, 2007). The
potential that an even more effective isoform of this gene exists is highly clinically
relevant. Future studies need to focus first on the mechanism of action of IL-2482,3,5.
The protein product of this splice variant would be very small, and we have thus far been
unable to detect it. The next step may be to determine if it is interacting functionally with
the full-length IL-24 protein, as this is the proposed function of IL-24 Isoform 2 (mda-7s)
(Allen et ah, 2004). As we have been unable to isolate the protein product, it is possible
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that it is functioning at the RNA level; gaining understanding of such a function would be
highly innovative.

Conclusions
At the beginning of this study, we posed several questions. How can an external
event modify the expression of a splice factor? Would that altered expression result in
splicing changes? And how might the different splice isoforms of a target gene affect
cellular function? By examining the splice factor SFRS6, and the upstream and
downstream events related to its expression, we have elucidated one way in which a cell
can respond to stress (in this case DNA damage) by modifying its splicing. Specifically,
we have identified how a cell can respond to DNA damage differently based upon its p53
status. In the absence of functional p53, SFRS6 expression is up-regulated. This response
is abrogated, however, if p53 binds to the REs on the SFRS6 promoter. The up-regulation
of SFRS6 affects the splicing of several genes; in this study we have examined IL-24. Our
examination has revealed five novel splice isoforms of IL-24 that differentially induce
apoptosis. One of these isoforms in particular has a dramatic effect on the cancer cells we
studied, and has potential for future use in cancer gene therapy.
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